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Abstract
Cellular adaptation to hypoxia involves downregulation of energy-consuming processes such as
macromolecular synthesis, and leads to tumor aggressiveness and resistance to therapies for many solid
cancers. To delineate mechanisms underlying this process, I carried out a transcriptome-wide study to
measure hypoxia-mediated changes in gene expression and alternative splicing in in vivo and in vitro
models of hypoxic head and neck carcinoma (HNC) cells. These data represent the first nucleotideresolution study of the hypoxic transcriptome of HNC cells in vivo and in vitro. This investigation
uncovered a global downregulation of genes known to regulate RNA processing, including a significant
number of genes involved in splicing catalysis. Exon-level analyses classified >1,000 mRNAs to be
affected by alternative splicing, and led to the discovery of a unique retained intron in the master regulator
of translation initiation, EIF2B5. In this dissertation, I will describe a previously uncharacterized
mechanism by which a hypoxia-mediated retained intron in EIF2B5 leads to a truncated isoform that
opposes full-length eIF2Bε to inhibit translation. A functional investigation of this hypoxia-induced
isoform confirmed that expression of the truncated 65kDa isoform of eIF2Bε confers a survival
advantage to HNC cells under conditions of hypoxia. Moreover, expression of this isoform was observed
in solid tumors of patients with HNC in a stage-dependent manner. Additional work to uncover -cis and
-trans regulators of EIF2B5 splicing identified several factors that influence intron retention in EIF2B5: a
weak splice site with an alternate splice site at the retained intron, hypoxia-induced expression of the
splicing factor SRSF3, and increased binding of total and phospho-Ser2 RNA polymerase II (RNAPII)
specifically at the intron retained under hypoxia. Altogether, these data reveal differential splicing as a
previously uncharacterized mode of translational control under hypoxia and are supported by a model in
which hypoxia-induced changes to co-transcriptional processing lead to selective retention of an intron
containing a premature-termination codon in EIF2B5.
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ABSTRACT
TRANSCRIPTOME-WIDE ANALYSIS OF HYPOXIC CANCER CELLS IDENTIFY
ALTERNATIVE SPLICING AS A MECHANISM TO INHIBIT TRANSLATION
Lauren K. Brady
Dr. Constantinos Koumenis

Cellular adaptation to hypoxia involves downregulation of energy-consuming
processes such as macromolecular synthesis, and leads to tumor aggressiveness and
resistance to therapies for many solid cancers. To delineate mechanisms underlying this
process, I carried out a transcriptome-wide study to measure hypoxia-mediated changes
in gene expression and alternative splicing in in vivo and in vitro models of hypoxic head
and neck carcinoma (HNC) cells. These data represent the first nucleotide-resolution
study of the hypoxic transcriptome of HNC cells in vivo and in vitro. This investigation
uncovered a global downregulation of genes known to regulate RNA processing,
including a significant number of genes involved in splicing catalysis. Exon-level
analyses classified >1,000 mRNAs to be affected by alternative splicing, and led to the
discovery of a unique retained intron in the master regulator of translation initiation,
EIF2B5. In this dissertation, I will describe a previously uncharacterized mechanism by
which a hypoxia-mediated retained intron in EIF2B5 leads to a truncated isoform that
opposes full-length eIF2Bε to inhibit translation. A functional investigation of this
hypoxia-induced isoform confirmed that expression of the truncated 65kDa isoform of
eIF2Bε confers a survival advantage to HNC cells under conditions of hypoxia.
Moreover, expression of this isoform was observed in solid tumors of patients with HNC
in a stage-dependent manner. Additional work to uncover -cis and -trans regulators of
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EIF2B5 splicing identified several factors that influence intron retention in EIF2B5: a
weak splice site with an alternate splice site at the retained intron, hypoxia-induced
expression of the splicing factor SRSF3, and increased binding of total and phosphoSer2 RNA polymerase II (RNAPII) specifically at the intron retained under hypoxia.
Altogether, these data reveal differential splicing as a previously uncharacterized mode
of translational control under hypoxia and are supported by a model in which hypoxiainduced changes to co-transcriptional processing lead to selective retention of an intron
containing a premature-termination codon in EIF2B5.
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CHAPTER 1
Introduction to regulation of gene expression
in hypoxic cancer cells

A portion of this chapter includes work previously published as the book chapter, “In Vivo
Interrogation of the Hypoxic Transcriptome of Solid Tumors: Optimizing Hypoxic Probe
Labeling with Laser Capture Microdissection for Isolation of High-Quality RNA for Deep
Sequencing Analysis” (Brady, Popov and Koumenis, Adv Exp Med Biol, Vol. 899, 2016).
Reprinted with permission of Springer Nature.

Introduction

Understanding how gene expression is controlled is fundamental to identifying
biological pathways and regulatory mechanisms that govern cellular responses to
physiologic stresses, such as hypoxia. In the context of tumor biology, differential gene
expression studies have revealed that specific features of the tumor microenvironment,
such as hypoxia, influence the growth and aggressiveness of tumors (4, 5). Moreover,
hypoxia has been determined to negatively impact the therapeutic response of tumors in
patients (6, 7). Many of these negative effects, such as aggressiveness of tumors, arise
due to the ability of cancer cells to adapt to hypoxic environments. An initial step in
defining the relationship between hypoxia and tumor growth, survival and resistance to
therapy is to determine how cancer cells adapt to reduced availability of oxygen in
tumors. Work in this area has demonstrated that cancer cells adjust to hypoxia by
downregulating energy-consuming processes, such as translation (8).
In order to advance our understanding of how cellular adaptation to hypoxia is
controlled, the work described in this dissertation explores the role of alternative splicing
in establishing gene expression programs that impact cellular response to hypoxia.
Alternative splicing and RNA processing represent understudied areas in determining
how hypoxia gene expression programs are controlled. This dissertation includes a
deep investigation of changes in individual transcript levels and alternatively spliced loci
to provide an additional layer of information about how gene expression is fine-tuned in
hypoxic cancer cells. These data revealed novel insights into adaptation to hypoxia in
head and neck cancer cells. Chapter 1 contains a summary of the history and
significance of hypoxia-regulated gene expression, evolution of technical approaches to
2

specifically investigate hypoxic cells, and overarching scientific aims of our research to
elucidate the role of alternative splicing in cellular adaptation to hypoxia.

Biological consequences of tumor hypoxia
Hypoxia, a state of reduced cellular oxygen, influences cellular survival, growth and
metabolism by triggering widespread changes in gene expression (9). While transient
hypoxia occurs from an imbalance between oxygen supply and consumption in normal
tissues and during development, hypoxia (acute or chronic) is a key feature of solid tumors
that contributes to therapeutic resistance and positively correlates with tumor
aggressiveness (10). Acute hypoxia, which may last only minutes to hours, refers to
fluctuation in oxygen supply due to inadequate blood flow and may only affect parts of the
tumor (11). Chronic hypoxia accounts for the majority of hypoxia found in tumors. This
largely occurs due to limitations in oxygen diffusion, often caused by networks of irregular
vessels and increased distances between vessels in tumors compared to normal tissues
(12, 13). The poor vasculature and decreased blood supply to distal regions in solid tumors
creates separate, oxygen-poor microenvironments within the tumor tissue.
Hypoxic tumors exhibit resistance to radiation therapy and some chemotherapies
due to lack of sufficient oxygen essential for the formation of free radicals necessary to
cause DNA damage (14). Low oxygen levels and associated tissue acidity also decrease
cellular uptake of chemotherapies and result in reduced drug delivery to tumors (14).
Moreover, development of blood vessels is tightly regulated by expression of proangiogenic factors (i.e. VEGF) and anti-angiogenic factors (i.e. thrombospondin), which
respond to demand for oxygen and nutrients. Expression of these and other angiogenic3

related factors is regulated by the Hypoxia Inducible transcription Factor HIF-1 (15).
Overexpression of pro-angiogenic factors and increased cellular growth rates often
disrupts the network and structure of blood vessels in tumors. Uncovering a deeper
knowledge of which genes and isoforms are differentially expressed in hypoxic regions of
tumors will provide a better understanding of how pathways that impact resistance to
therapy, such as angiogenesis, are regulated.

Using hypoxia gene expression signatures to understand the biology of the tumor
microenvironment
There are several solid tumors that are considered more hypoxic than others, such as:
gliobastoma multiforme, head and neck carcinomas, breast, cervix and prostate (16-18).
Due to the biological pathways that undergo changes in gene expression under hypoxia,
there is a negative correlation between the level of hypoxia in tumors and overall survival
in patients of many solid cancers, including head and neck squamous cell carcinoma
(HNSC) (19). Pioneering work to establish a hypoxia “metagene” signature used
microarray data from patients with HNSC and discovered a subset of genes whose
expression that strongly correlated with levels of tumor hypoxia (20, 21). Currently,
hypoxia “metagene” expression signatures are accepted as a surrogate method to
classify tumor hypoxia for HNSC and other solid malignancies, including breast and
prostate cancer (20, 21).
Even though regulation of mRNA and miRNA have been extensively studied in
vitro (22, 23), in vivo analysis of hypoxic tumors has been limited due to small quantities
of poor-quality RNA when isolated from immunohistochemical samples using traditional
4

methods. Although in vitro hypoxic conditions can represent oxygen levels in tumors,
these conditions do not take into the account many other factors present in the tumor
microenvironment that contribute to physiologic stress like low nutrient levels, low pH,
infiltrating immune cells and necrotic tissue, or, more critically, the interplay between these
factors and the effect on gene expression. A prime example of this is lactic acidosis, which
when it co-occurs with hypoxia, results in reduced stabilization of HIF-1 and counteracts
the usual induction of hypoxia-responsive genes. This occurs in part due to lactic acidosis
stimulating the Unfolded Protein Response (UPR) as well as an inflammatory response
(24).
Studying changes in gene expression due to stresses that arise in the tumor
microenvironment, such as hypoxia or acidosis, can be simplified by utilizing in vitro
systems. The value in utilizing in vitro approaches is that it enables the isolation of
specific stresses within the tumor microenvironment, such as hypoxia. However, it is
crucial to pair these studies with the respective in vivo models to gain a more complete
understanding of the basic biology of the tumor microenvironment. As a result, there is
an immediate need for improved methods to isolate DNA and RNA from tumor samples.
To achieve this goal, our group previously developed an approach utilizing a
combination of EF5 staining, laser-capture microdissection (LCM) and modification to
traditional RNA purification methods to specifically isolate high-quality RNA from hypoxic
and normoxic regions for gene expression studies (25). Imaging techniques utilizing
oxygen-sensitive molecules followed by immunofluorescence staining offer the
advantage as being a safe and non-invasive method for identifying hypoxia in patient
tumors. EF5 is an FDA-approved fluorinated derivative of etanidazole, that is reduced in
regions of hypoxia where it covalently binds to adjacent proteins and DNA. This stable
5

binding makes EF5 ideal for use as 18F-EF5 for PET scans in patients or animals, or
allows for subsequent staining with anti-EF5 antibodies conjugated to fluorochromes,
such as Cy3 or Cy5, for downstream microscopy-based applications at the bench (26).
EF5 is also a lipophilic molecule that is readily taken up by tumor tissue. Moreover, its
binding does not rely on pH, both features which offer the advantage of increased
biodistribution compared to other hypoxia markers (26). Use of molecular hypoxia
markers have enabled the collection of clinical data to strengthen the finding that hypoxic
tumors are indeed correlated with poor prognosis. In addition, these methods allow safe
and precise staining of hypoxic tissues, which in combination with the laser-capture
microdissection (LCM) technology, has allowed for the optimization and development of
downstream methods for excising high-quality RNA for gene expression analyses.
Marotta et al., were the first to publish on use of LCM to extract high-grade RNA
from specific hypoxic and normoxic tumor sections for subsequent microarray analysis.
Specifically, gliosarcoma cells were used to establish tumors in a rodent model. The
bioreductive dye, EF5, was used to specifically label hypoxic regions of the tumor tissues,
allowing for the study of gene expression differences across normoxic and hypoxic tissues
from the same tumor (25). This same approach was used to carry out RNA-sequencing of
normoxic and hypoxic tissues of a murine model of head and neck cancer (see Figure 1AE for overview). I used these data to investigate hypoxia-mediated changes in regulation
of alternative splicing, which is described in Chapter 2. In addition, several variations were
made to the protocol to specifically enrich for mature mRNAs (Figure 1D,E). First, oligodT selection was used to specifically enrich for poly-adenylated mature mRNAs (which
comprise only 3-5% of total RNA) for the specific goal of evaluating gene expression and
mRNA splicing. Additionally, an enzyme treatment was used to deplete the samples of
6

ribosomal RNAs, which can account for as much as 80% of the total RNA material in the
cell (27).

Figure 1.1: Experimental overview for in vivo labeling paired with LCM for RNA
sequencing of hypoxic tumors. A: Representative image of injection of EF5 into an
animal model of tumor hypoxia. B: After tumor is excised, membrane slides are prepared
with antibodies against EF5 to visualize areas of hypoxia, stained in red. C: Laser capture
microdissection (LCM) can then be used to remove normoxic ((i) pre-LCM, (ii) post-LCM)
and hypoxic ((iii) pre-LCM, (iv) post-LCM) tissue. Panels a–c modified from [23]. D:
Following RNA extraction, cDNA libraries are prepared using mRNA depleted of rRNAs
and annealed with primers specific for the sequencing platform. E: Libraries are
sequenced and the sequences are aligned to a reference genome.
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Regulation of mRNA levels in hypoxic tumors
There are several mechanisms that cooperate to control mRNA levels in hypoxic cells.
Understanding how the expression response to hypoxia is controlled is the basis to
identifying which pathways mediate the cellular adaptation to hypoxia and identifying
methods to target these pathways in tumors for therapeutic benefit. Hypoxia-responsive
genes have historically been studied in relation to the major Hypoxia Inducible
transcription Factors (HIFs). HIF-1, is a heterodimeric protein which includes an oxygenresponsive alpha subunit and constitutively active beta subunit. Under normoxic
conditions, HIF-1 is constantly synthesized and degraded (28). In the presence of normal
oxygen concentrations, HIF-1 is hydroxylated on proline residues, where it interacts with
von Hippel-Lindau factor (VHL), becomes ubiquitinated and is eventually degraded via the
proteasome. Hydroxylation also prevents co-factor binding to HIF-1a, further inhibiting its
transcription regulatory function. Decreased oxygen prevents this process, which results
in stabilized HIF-1 protein (28, 29). These conditions permit HIF-1a proteins to
heterodimerize with a beta subunit and induce transcription of target genes involved in
glucose metabolism, cell survival and cell migration (30).
Some well-known examples of HIF-1α transcriptional targets are vascular
endothelial growth factors (VEGF) involved in angiogenesis, GLUT1, also known as
SLC2A, glucose transporter involved in glycolysis, and carbonic anhydrase IX (CA9),
which is a regulator of cellular pH (31). Expression of these and other HIF-1α regulated
proteins also correlate with the metastatic potential of tumors and therapeutic resistance
(32).

8

Translational control in hypoxic cells
Transcriptional activation of hypoxia-responsive genes represents one component
of how mRNA levels are controlled under conditions of low oxygen. However, various
regulators in addition to transcription factors, including RNA binding proteins (RBPs) and
non-coding RNAs, influence the stability and localization of mRNAs under hypoxia (3335). For example, the RBPs HuR and PTB bind to major regulators of hypoxic response
such as HIF1α (36, 37) and miRNA-199a (38) to regulate stability and localization of these
RNAs. Factors such as these directly impact the potential of an mRNA to be translated.
Moreover, both nonsense-mediated decay (NMD) and translation are globally
downregulated in hypoxic cells in an eIF2α phosphorylation-dependent manner (8, 39). In
the context of hypoxia, phosphorylation of eIF2α is mediated by the kinase, PERK (8);
however, other activators of the unfolded protein response (UPR) such as nutrient
deprivation, also induce phosphorylation of eIF2α by GCN2 (40, 41).
The NMD pathway is an evolutionarily conserved mechanism to identify transcripts
that contain premature-termination codons (PTCs) and initiate the decay of these
transcripts to prevent their translation into proteins. Typically, NMD surveillance
recognizes stop codons as premature if the stop occurs more than 50 nucleotides
upstream of a splice junction (42). Bioinformatic analyses have approximated that up to
20-35% of alternatively spliced transcripts could contain PTCs and become targets of
nonsense mediated decay (NMD) (43, 44); however in conditions where NMD is inhibited,
transcripts can escape decay and become translated into truncated proteins (45).
One of the chief ways that tumor cells overcome hypoxic stress is by
downregulating translation which was demonstrated to be critical for cell survival under
9

extreme hypoxia (8). Under conditions of normal oxygen, protein synthesis requires the
five-member eIF2B complex, which binds eIF2α and exchanges GDP for GTP to initiate
translation (46, 47). The eIF2Bε subunit is a necessary component of this complex which
contains both the active guanine nucleotide exchange factor (GEF) domain and a region
for association with eIF2α (47). In conditions of hypoxia, eIF2α is phosphorylated (8) and
translation initiation is unable to occur when eIF2B complexes bind phospho-eIF2α.
However, this phosphorylation can be removed by GADD34 and is not long-lasting (48,
49). Intriguingly, in cells stably expressing a form of eIF2α with an S51A mutation
rendering these cells unable to be phosphorylated, translation initiation resumed under
hypoxia, but only to approximately 75% of the level observed in control cells (8). These
data suggested the existence of additional mechanisms to sustain reduced protein
synthesis in hypoxic cancer cells. Chapter 3 will describe how an investigating of hypoxiamediated changes in splicing uncovered a previously uncharacterized hypoxia-responsive
isoform of eIF2Bε which acts to inhibit translation and promote survival of hypoxic cancer
cells.

The role of alternative splicing in the cellular response to hypoxia
There is strong evidence to support that alternative splicing represents an
additional layer of control in the regulation of hypoxia gene expression programs. Initial
studies have identified select targets of HIF-1a to undergo alternative splicing (50).
Moreover, hypoxia-induced changes in the expression of certain non-coding RNAs occur
due to splicing and may impact regulation of the DNA damage response in conditions of
low oxygen (51). Moreover, HIF-1α impacts the splicing of several of its transcriptional
10

target genes, including ADM and CA9 (50, 52). It remains unclear what the biological
consequences of altered splicing in hypoxic tumors may be and what HIF-independent
factors regulate splicing in the hypoxic tumor microenvironment. These two understudied
areas of hypoxic biology were a major inspiration for the scientific goals of this dissertation,
which I will explain in greater detail at the conclusion of Chapter 1.
Mechanistically, a connection between regulation of RNA splicing and altered
signaling within the tumor microenvironment has recently emerged; several major
signaling pathways known to be overactive in cancer which impact cell growth, survival
and angiogenesis, also impact expression and processing of mRNA isoforms (53). Several
kinases known to phosphorylate major RBPs and splicing factors are also hypoxiaresponsive (54). In addition, some splicing factors, including SF3B1, are upregulated in a
HIF1α-dependent manner under physiological conditions of hypoxia in cardiac myocytes
(55); however, it remains unclear precisely how mRNA splicing is regulated during periods
of oxygen deprivation in cancer cells and what the resulting biological implications are.
While regulation of RNA splicing can be varied in a tissue-specific or under physiologic
stress, it is important to begin with a summary of what has been fully characterized about
this process in normal cells.

Regulation of mRNA splicing & determinants of intron retention
Splicing is the biochemical reaction by which introns are removed from pre-mRNA to
result in mature messenger RNAs typically consisting of exons and terminal untranslated
regions (UTRs) (56). This reaction is catalyzed by the spliceosome complex of RNAbound proteins, RNPs, which recognize and bind conserved RNA sequences, and is
11

influenced by additional RNA binding proteins such as splicing factors (56). For more
than 99% of mRNAs, splicing occurs via assembly of the major spliceosome containing
five small nuclear ribonucleoprotein or snRNP complexes (as reviewed in (57)). Briefly,
this process entails U5 and U4/U6 tri-snRNP assembly, followed by U1 binding at the 5’
splice site, U2 binding at the branch-point sequence and U2AF binding at the 3’ splice
site (Figure 2). This step is broadly defined as exon definition and is largely influenced
by highly conserved -cis RNA sequences. These sequences include the splice sites,
intron sequence around the branch-point sequence and splicing enhancer or silencer
sequences located in introns or exons, and often impart a stronger influence when
located near a splice site (58). Generally, the enhancer and silencer motifs are bound by
serine/arginine-rich (SR) proteins and heterogeneous nuclear ribonucleoproteins
(hnRNPs) to promote or repress splicing, respectively (59, 60).

Figure 1.2: Conserved sequences involved in the regulation of RNA
splicing. The conserved splice sites are highlighted at each of the exon
junctions flanking this intron. Exons shown as blue rectangles and intron
depicted as blue line drawn in between. Regulatory RNA/protein complexes
shown and labeled below.
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Although these sequences are highly conserved, variation in the splice site can also
influence splicing efficiency and splice site choice. For example, weak splice sites may
contribute to inefficient splicing or promote usage of alternate splice sites under specific
conditions, such as changes to the elongation rate of RNA polymerase II (RNAPII) (61).
The splicing of many genes is sensitive to changes in the activity of RNAPII since
splicing occurs co-transcriptionally. The kinetics of elongating RNAPII influences the
spliceosome interaction with RNA, such that slower or faster RNAPII can alter mRNA
splicing patterns. This was best described in a genetic model of RNA polymerase
elongation rate mutants, in which cells expressing a slower elongating RNAPII exhibited
an increase in retained introns which contained relatively weaker splice sites as opposed
to introns unaffected by a slower transcription rate (61).
In combination to the role of -cis RNA sequences in determining splice site
decisions, changes in cell signaling alter the expression and activity of splicing factors.
More than 95% of multi-exonic genes can be alternatively spliced in a tissue-specific
context or due to changes in cellular signaling triggered by physiological or extrinsic
stresses. For example, global downregulation of many key splicing factors, including
SF3B1 leads to intron retention as a mechanism to promote maturation of granulocytes
during hematopoiesis (3). Since many of the same biological pathways that contribute to
normal development also influence tumor development, it is unsurprising that over-active
signaling networks in tumors can significantly impact patterns of mRNA splicing.

13

Altered regulation of splicing in cancer
Many of the fundamental pathways that affect normal tissue and tumor development are
influenced by over-active signaling networks. In tumors, some of these signaling
networks lead to overexpression of kinases which act to phosphorylate and influence
biological processes within the tumor microenvironment. A key implication of hyperactivated kinases is their impact on factors that regulate mRNA processing and splicing.
For example, many tumors contain activated EGFR signaling, which leads to induction of
kinases, such as SRPK1 and CLK1. These kinase activate the major class of serinearginine rich splicing factors (including SRSF1, SRSF2 and SRSF3) which mediate
splicing and expression of mRNA isoforms involved in apoptosis, cell growth and
angiogenesis (reviewed in (53)).
Interestingly, SF3B1 is described as the most commonly mutated splicing factor
in cancer (62). This splicing factor is critical and suggested to be involved for recognition
of nearly all 3’ splice sites (63). Mutations in SF3B1 have been observed in patients with
leukemia, pancreatic cancer, uveal melanoma, breast cancer and bladder cancer (62).
Many additional splicing factors even when unmutated may act as proto-oncogenes. Key
examples include SRSF1 and SRSF3. In breast cancer, increased levels of SRSF1 lead
to alternatively spliced isoforms of BIM and BIN1 that become unable to carry out their
pro-apoptotic functions (64). Decreased levels of SRSF3 lead to an isoform of p53 that
initiates p53-induced senescence (65).
Collectively, these studies have identified common genome-wide alterations in
patterns of splicing, including an increase in retained introns in tumors relative to normal
tissues (66, 67). Yet how intron retention is controlled in cancer cells remains poorly
14

understood. Exploring the functional consequences of intron-containing transcripts and
investigating regulators of intron retention in the context of hypoxic cancer cells are
overarching aims of the research in Chapter 3.

Scientific Aims: Investigating the link between hypoxia & alternative splicing
The overall goal of this work is to characterize alternative splicing in hypoxic
cancer cells, gain mechanistic insight into this process and identify the most biologically
impactful hypoxia-responsive mRNA isoforms. Based on previous data describing
various stress-responsive proteins in addition to transcription factors that influence
mRNA levels in hypoxic cells, my overarching hypothesis is that hypoxia leads to
widespread changes in regulation of alternative splicing in head and neck cancer cells.
For the first aim of my dissertation, I set out to measure changes in alternative splicing in
in vivo and in vitro models of hypoxic HNSC cells at nucleotide resolution. In the second
aim of this dissertation, my goal was to carry out a functional investigation of the
biological impact of select hypoxia-responsive isoforms. One of the strongest candidates
that arose from the data was a hypoxia-induced retained intron in the major regulator of
translation initiation, EIF2B5. I hypothesized that under conditions of hypoxia, retention
of this intron creates a premature-termination codon resulting in a truncated protein
isoform of eIF2Bε. This truncated isoform was predicted to lack the functional GEF
domain, thus I tested if the hypoxia-induced truncated isoform of eIF2Bε acted opposite
to the full-length isoform to inhibit translation.
Regulation of intron retention has been identified as a way to fine-tune gene
expression during development (3). Widespread retention of introns has also been
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observed in most solid cancers (66). The work described in Chapters 2 and 3 further
establishes the role of mRNA splicing in cellular adaptation to hypoxia and identifies
intron retention as a component of gene expression regulation in hypoxic cells. Chapter
2 specifically characterizes changes in individual mRNA transcript levels and begins to
explore how regulation of RNA processing and mRNA splicing is altered in hypoxic cells
in vivo and in vitro. Data from Chapter 3 will include a deeper exon-level analysis of
alternative splicing by examining splice junction reads to study expression levels at
specific loci that change under hypoxia. This analysis allowed me to address scientific
questions such as, are there particular types of splicing (such as skipped exons or
retained introns) that are differentially regulated in hypoxic cells? What is the biological
consequence of hypoxia-mediated changes in splicing? And do any of these changes in
splicing lead to protein isoforms that differ in function compared to the isoform(s)
expressed in normoxic conditions?

Conclusion
The additional layers of biological information that are uncovered by deeply sequencing
tumor RNA in combination with in vitro samples to specifically study the effects of
hypoxia will bring insight into control of splicing in hypoxic cancer cells. The novel
findings which will be presented in the following chapters highlight the significance of
examining regulation of gene expression at nucleotide resolution to identify stressresponsive isoforms which carry out critical biological functions under specific conditions.
Here, I present a functional investigation of the role of a hypoxia-induced dominant-
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negative isoform of eIF2Bε as one of the first examples of how splicing can contribute to
cellular adaptation to hypoxic stress.
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CHAPTER 2
Transcriptome analysis of head and neck cancer cells
in vivo & in vitro identifies downregulation
of RNA processing & splicing under hypoxia
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Introduction
Tumor hypoxia strongly correlates with reduced overall survival in patients of many types
of cancer, including head and neck (68). Uncovering how hypoxia contributes to
tumorigenesis and leads to poor prognosis has proven to be a multi-faceted and
complicated research goal. Advances in techniques to specifically label and probe
hypoxic cells for gene expression profiling have led to the identification of well over
1,000 hypoxia-responsive genes (25). A smaller subset of these genes, including key
regulators of pathways impacting angiogenesis, oxygen metabolism, cell migration and
protein synthesis, are universally and robustly regulated across different solid tumor
types, including breast, head and neck, and prostate (20, 21). Differential expression of
these genes has been used as a marker in lieu of other invasive methods to identify and
quantify hypoxia in tumor samples from patients to gain prognostic and biologic data.
This information has the potential to guide treatment options for patients if scientists can
identify the genes underlying hypoxia-mediated resistance to therapy and metastasis,
but this goal has yet to be realized due to several obstacles. Two of the greatest
challenges in applying this basic research to the clinic include developing a system to
investigate hypoxia within the tumor microenvironment without using whole,
homogenized tumor samples (which do not account for tissue heterogeneity); and
identifying precisely which genes are targetable for impacting the largest effects on
tumor survival and response to treatment. Additionally, as greater than 90% of human
genes can be expressed as multiple mRNA isoforms which often yield protein isoforms
with distinct functions (69, 70), there is a need to expand current gene expression
studies to include isoform-level changes.
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To address these challenges, I utilized data obtained using a method previously
developed by our group which enabled the first characterization of hypoxia-induced
changes in gene expression from in vivo samples (25). This method uses laser capture
microdissection (LCM) of tumors injected with the FDA-approved hypoxia probe EF5,
which is an established and effective way to identify hypoxic areas of tumors in both
patients and animal models of cancer (71). This probe readily diffuses into tumors where
it is reduced to an active radical exclusively in oxygen-poor regions, and covalently binds
with surrounding proteins and DNA. Using this method, RNA was isolated from normoxic
and hypoxic regions of head and neck tumors established in mice for deep sequencing.
To build upon this study and allow for the controlled isolation of effects due to hypoxia
alone, I also prepared corresponding in vitro samples. Together, these data enabled me
to investigate regulation of gene expression and mRNA splicing in hypoxic head and
neck cancer cells at base-pair resolution.
Surprisingly, although alterations in splicing have been observed in several
cancers and occur in pathways which influence (and are influenced by) tumor hypoxia,
the regulation of splicing in hypoxic tumors and the impact of hypoxia-responsive
isoforms on tumor survival and patient outcome has yet to be investigated genome-wide.
For example, the major splicing factor SF1 is directly upregulated transcriptionally in
cancers with overexpressed c-Myc transcription factor. This in turn mediates splicing of
key genes such as Bcl family members and Caspases involved in cell death, VEGF
genes involved in angiogenesis and additional genes impacting invasion and metastasis
(53). Additionally, a handful of genes have been described as alternatively spliced in
hypoxic cancer cells, including core target genes of the hypoxia-inducible transcription
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factors (HIFs), such as the pyruvate dehydrogenase kinase, PDK1 (50); however, the
biological impacts of these changes have yet to be evaluated.
My goal is to investigate the link between hypoxia, splicing and cell survival in a
model of head and neck cancer and will begin by assessing whether select alternatively
spliced isoforms establish properties of the hypoxic tumor microenvironment, such as
reduced protein synthesis (which is described in greater detail in Chapter 3). Head and
neck cancer (HNC) is one of the solid malignancy most adversely affected by hypoxic
fractions. Because patients affected by HNC have been deeply studied at a genetic level
to uncover molecular markers of hypoxia (21), HNC is a model disease system in which
to investigate the biology of hypoxic tumors. Initial work in this area importantly
established that the level of hypoxia in tumors of HNC patients was associated with a
strong and reproducible hypoxia “metagene” signature, comprised of many HIF-1α
activated genes yet also including some genes consistently repressed under hypoxia.
Gene expression data from a large cohort of HNC patients confirmed that patients with
the strongest hypoxia metagene signatures exhibited significantly reduced overall
survival compared to those with weaker metagene signals (21). Moreover, these initial
studies have been expanded to verify that the hypoxia metagene initially described in
HNC is quite robust and nearly universal, and was further refined to successfully classify
patients affected by additional solid cancers, including breast and prostate (20).
To gain a deeper understanding of the biology of hypoxia in HNC, RNA was
isolated from normoxic and hypoxic regions of tumors established in athymic mice from
human head and neck squamous cell carcinoma SQ20B cells and used for deep
sequencing. For this study, the bio-reductive dye, EF5, was used to specifically label
oxygen-deprived areas of tumor tissue. EF5 was selected as a cellular hypoxia label
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because it is an FDA-approved molecule that has been used in the clinic to safely label
hypoxic tissues in patients (26). RNA was also isolated and prepared for sequencing
from the same SQ20B cells grown in vitro under hypoxic and normoxic conditions. Cells
were grown in 0.5% oxygen for 16h because this falls within the range of oxygen levels
observed in hypoxic tumors and accounts for prolonged exposure to these conditions
which occurs in vivo. This approach allowed us to deeply investigate transcriptome
changes due to hypoxic stress alone, without the influence of additional cellular stresses
such as nutrient deprivation or changes in pH, which occur within the tumor
microenvironment in an in vivo setting. The following data represent the first comparative
hypoxic transcriptome study at nucleotide resolution of HNC in vivo and in vitro.

Results
Changes in individual mRNA isoform expression patterns represent an additional
layer of hypoxia-regulated gene expression
The sequencing data were aligned and transcripts were assembled using the RefSeq
human genome version 19 reference; expression levels were quantified as fragments
per kilobase of transcript per million mapped reads (FPKM) for known RefSeq transcripts
(72, 73). To achieve a finer resolution of hypoxia-regulated changes in expression,
individual mRNA transcripts were examined to define gene expression at an isoform
level. For the in vitro dataset, 18,915 individual mRNA transcripts were expressed
(FPKM ≥ 0.5) in either normoxic or hypoxic SQ20B cells. For the in vivo samples, there
were 18,573 transcripts detected (mean FPKM ≥0.5). Of the total 16,277 transcripts
detected in both the in vivo and in vitro datasets, there was a modest positive correlation
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in hypoxia-mediated changes in expression (Spearman correlation ρ=0.49, transcripts
filtered for differentially expressed in hypoxia vs. normoxia P<0.05, FDR< 5%).
The in vitro data revealed 2,617 hypoxia-responsive transcripts (P<0.05, FDR<
5%). Fold change in expression in hypoxia compared to normoxia ranged from -10.4 to
76.1. A similar trend was observed for the in vivo study which contained 2,263
transcripts that significantly changed expression under hypoxia (P<0.05, FDR<5%), with
fold-change in expression values ranging from -52.1 to 45.8. Hypoxia-induced transcripts
(represented by 628 in vivo and 1,142 in vitro) were the subset of mRNAs which
exhibited the strongest correlation (Spearman correlation ρ=0.501, Fig 2.1), with 268
transcripts representing 262 unique genes significantly induced in both datasets. The
expression profiles are consistent with genes previously reported to be regulated by
cellular oxygen levels. Gene ontology analysis confirmed that transcripts commonly
induced in both datasets are significantly enriched for hypoxia-responsive genes and
genes involved in glycolysis, and HIF-1α target genes.

Figure 2.1: Comparison of hypoxia-induced mRNAs from in vivo and in vitro
studies of head and neck cancer cells. For correlation, mRNAs identified as
significantly induced in hypoxic compared to normoxic cells (P<0.05 for at least one
study). Log2 fold-change in expression is plotted, with corresponding Spearman
ranked correlation coefficient. Venn diagrams
represent the number of mRNAs
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significantly induced for each dataset (P<0.05). Top gene ontology terms with
examples listed below (DAVID Gene Ontology, FDR<%5).

Many targets of HIF-1α were among the most induced transcripts, including
VEGFA, ADM and CA9. Select HIF-1α targets were chosen for validation and showed
similar induction patterns for both RNA-seq and RT-qPCR methods (Fig 2.2).
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Figure 2.2: RT-qPCR validation of select HIF-1α target genes. For
each set of graphs, RNAseq data shown to the left and corresponding
RT-qPCR shown at right (average of three, independent experiments
+/- S.E.M.) for SQ20B cells in normoxia or 0.5% O2 for 16h.

There were similar numbers of repressed transcripts in hypoxic samples from
each study, including 1,475 transcripts from 1,454 unique genes from the in vitro data,
and 1,635 transcripts from 1,570 genes in the in vivo study. Altogether, the correlation
between the two studies for this set of transcripts was modestly weaker compared to
hypoxia-induced genes, (Spearman correlation ρ=0.262, Fig 2.3) even though the
overlap included a larger number of transcripts than hypoxia-induced genes.
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Figure 2.3: Comparison of hypoxia-repressed mRNAs from in vivo and in vitro
studies of head and neck cancer cells. For correlation, mRNAs identified as
significantly repressed in hypoxic compared to normoxic cells (P<0.05 for at least one
study). Log2 fold-change in expression is plotted, with corresponding Spearman ranked
correlation coefficient. Venn diagrams represent the number of mRNAs significantly
repressed for each dataset (P<0.05). Top gene ontology terms with examples listed
below (DAVID Gene Ontology, FDR<%5).

I observed mRNAs downregulated in both the in vivo and in vitro samples to play
roles in several pathways involving DNA-protein interactions, including chromatin
organization, nucleosome assembly, cell cycle and RNA processing (Fig 2.3). Key
hypoxia-responsive transcripts in these categories encode histone proteins, core RNA
binding proteins including HNRNPF, SRSF3 and SNRPC, and various factors that
influence translation such as DKC1, NOP10, RRS1 and UTP6. Select highly induced
and repressed transcripts were validated by RT-qPCR (Fig 2.4).
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Figure 2.4: RT-qPCR validation of hypoxia-induced changes in mRNA
expression detected by RNAseq. A: Induced isoforms, with isoform 1,2, or 3
designated with number following gene symbol. B: Repressed isoforms, with
isoform 1,2 or 3 labeled. For each set of graphs, RNAseq data shown to the left
and corresponding RT-qPCR shown at right (average of three, independent
experiments +/- S.E.M.) for SQ20B cells in normoxia or 0.5% O2 for 16h.

These data revealed previously unreported patterns of differential isoform
expression in genes that are established to be stress-responsive at the total gene level.
26

By examining individual mRNA transcript-level differences, I observed differences in the
predicted biological functions of these isoforms as well. For example, isoform 1 of the
gene MAX-interactor 1 (MXI1) was preferentially induced under hypoxia compared to
isoform 3 (Fig 2.4). Additionally, there were functional differences between the isoforms
of MXI1, which differ at the amino-terminus thereby altering its ability to antagonize NMyc activity and impact cell proliferation (74, 75). Hypoxia selectively induced the
transcript which is translated into the shortest protein isoform. This isoform lacks 46
amino acids at the N-terminus compared to isoform 3 and is more than approximately
10kDa smaller than the full length MXI1 protein. Likewise, three isoforms of NDRG1
were induced by hypoxia, but isoform 2 exhibited the strongest induction (Fig 2.4).
Compared to the other two isoforms of NDRG1, isoform 2 lacks the proteolytic cleavage
site at Cys49-Gly50 due to an alternative transcription start site, resulting in 66 fewer
amino acids at the N-terminus. The isoforms of two additional genes, NEK6 and
FAM86C1, were validated as being selectively repressed under hypoxic conditions (Fig
2.4).

Analysis of genes expressing more than one mRNA isoform identified previously
undescribed hypoxia-responsive genes
In human cells, nearly all multi-exon genes are affected by alternative splicing and may
be expressed as more than one mRNA transcript variant. Alternative splicing can be
controlled in a tissue or cell-specific manner, but is also regulated through cell signaling
pathways in response to physiologic or extrinsic stresses. To determine the influence of
hypoxic stress on alterations in mRNA splicing, I first examined those genes expressed
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as multiple mRNA transcripts. Approximately 33% of the genes expressed in the in vivo
RNA-seq data (6122 of 18745) were expressed as more than one transcript. Similarly,
37% of genes observed in the in vitro study (5420 of 14651) were expressed as more
than one mRNA variant.
Instead of measuring total gene expression levels, the resolution of our data
allowed us to define hypoxia-responsive genes as any gene with one or more individual
mRNA transcript differentially expressed under hypoxia compared to normoxia (P<0.05,
FDR<5%). Using these criteria, of the genes that expressed more than 1 isoform, 1,216
(in vitro) and 2,347 (in vivo) contained at least one differentially expressed isoform.
Nearly 75% of these genes would not have been identified as regulated by hypoxia
without studying changes in individual transcript expression; only 331 of 1,216 genes (in
vitro) and 521 of 2,347 (in vivo) were identified in literature reports from traditional
microarray studies, including a curated database of over 2,000 genes reported as
regulated under conditions of low oxygen (76).
Because variation in expression of several mRNA transcripts of the same gene
could be masked when analyzing total gene expression changes (measured as the sum
of all transcripts), I next searched for genes with one or more differentially expressed
isoform that were not detected as hypoxia-responsive at the total gene level. For the in
vitro data, there were 61 of 1,216 genes with at least one differentially expressed
transcript which were not detected as differentially expressed at the total gene level in
our analysis. Of these 61, only 11 genes were previously reported as differentially
expressed in conditions of low oxygen (in vitro) confirming that these data led to the
discovery of 50 previously unreported hypoxia-responsive genes by measuring individual
mRNA levels as opposed to total gene levels. These 50 genes were functionally
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enriched for roles in protein localization (SEC24B, ARL17A, PLEKHA8, MLPH, STXBP5,
MON2, and EXOC1), MAPKK signaling (MAP4K3, DUSP22, and MAP3K13) and
regulation of RNA metabolism (ZNF519, JDP2, CTBP2, ZNF248, RBM5, NFAT5,
CREB3L2, SMARCA1 and ZFHX3) (DAVID Gene Ontology, P<0.05). The same analysis
was carried out for the in vivo dataset, and filtered for genes commonly found to be
hypoxia-specific in the in vitro set. This revealed 7 genes previously undescribed as
hypoxia-responsive which occurred in both the in vitro and in vivo datasets. These genes
included those predicted to carry out roles in protein localization (i.e. PLEKHA8, MLPH)
and RNA metabolism (ZNF519), and several other genes such as the SSH1
phosphatase involved in cell migration (77), the IP6K2 kinase linked to regulation of cell
death (78), a transcription factor of inflammatory genes (NFAT5) and the C16orf40 gene
of unknown function.

Determining the contribution of HIF-1α & hypoxia-response element (HRE)
sequences in regulating differential isoform expression
Because many hypoxia-induced changes in gene expression are influenced by HIF
transcription factor binding at conserved hypoxia-responsive element (HRE) sequences,
I carried out a meta-analysis to look at HIF-1α binding patterns (experimentally validated
by ChIP-seq (79)) and occurrence of HRE sequences at genes with differential isoform
expression under hypoxia. For in the in vitro genes, approximately 4.7% genes with a
hypoxia-responsive mRNA contain an HRE sequence reported to be bound by HIF-1α. If
I only considered those genes which expressed more than one transcript and were
affected by differential isoform expression, only approximately 5.3% of these genes
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contain HRE sequences or have previously reported HIF-1α binding. For the genes with
a hypoxia-responsive mRNA in vivo data, approximately 5.1% genes contain an HRE
sequence or HIF-1α binding site. The proportion of genes which expressed more than
one transcript and contain either an HRE or HIF-1α binding site was the same (5.0%).
Altogether, these data suggest alternative splicing and differential isoform expression of
hypoxia-responsive genes are regulated in an HRE-independent manner and that HIF1α is not a major contributor to global changes in splicing under hypoxia. This is
consistent with other reports, because although mRNA splicing occurs cotranscriptionally, regulation of transcription and mRNA splicing are distinct processes
which can impact different subsets of genes (80).

Key regulators of splicing catalysis are repressed under hypoxia
Intriguingly, there was an enrichment for hypoxia-responsive genes involved in
RNA processing, transcription elongation and RNA polymerase II regulation (P<0.05,
DAVID Gene Ontology Analysis (81)) and an overall repression of many regulators of
mRNA splicing (Figs 2.3, 2.5). This included many RNA binding proteins such as poly(A)
binding proteins, RBM (RNA binding motif) genes, and major splicing factors including
the serine-arginine rich factor SRSF1 and several SF3B family members. Strikingly, the
expression levels of these pathways were regulated similarly in both datasets (Fig 2.5).
Upon closer examination of genes involved in splicing catalysis, I observed a marked
repression of genes involved in nearly all major steps of splicing, including spliceosomal
assembly, exon definition and intron lariat removal (Fig 2.6).
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Figure 2.5: Hypoxia alters expression of
RNA processing and splicing factors.
Heatmap of expression fold-changes for RNA
processing genes significantly altered in
hypoxic cells (P<0.05 for at least one dataset).
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Figure 2.6: RNA-Seq expression data for in vivo & in vitro study of hypoxic
head and neck cancer cells reveals downregulation of genes involved in
splicing catalysis. Top panels describe the initial steps including binding at
conserved splice sites (at the intron:exon junction) and branchpoint sequences
(depicted in the intron). Lower panel includes genes involved in the regulation of the
final steps for intron removal. List of eukaryotic genes involved in catalysis steps
based on summary described from previous studies (3).
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Discussion
Next-generation sequencing analyses of hypoxic tumor microenvironments yield greater
resolution of transcriptome changes. The results from these transcriptome studies
provided an in-depth look into changes in mRNA levels and patterns of differential
mRNA isoform at a resolution that has yet to be described. The similarities observed in
the regulation of hypoxia-responsive genes in the in vivo and in vitro models of HNC
further establish EF5-labeling coupled with LCM as a validated technique for the specific
gene expression profiling of hypoxic cells within the tumor microenvironment. These
data also highlight the advantages of high-resolution RNA-sequencing data in studying
stress-responsive gene expression programs, as I could identify genes previously
unreported as hypoxia-responsive. Additionally, genes established as hypoxiaresponsive were shown to contain complex patterns of differential isoform expression
which may provide clues to hypoxia-specific isoforms which carry out distinct functions.
For example, NDRG1 encodes a stress-responsive cytoplasmic protein that activates
p53-mediated apoptosis and can suppress metastasis; hypoxia-induced alternative
splicing in this gene leads to expression of an isoform lacking a proteolytic cleavage site,
which would likely alter the function of the resulting protein (82). Similarly, isoform 2 of
the gene NEK6 is selectively repressed compared to other isoforms of NEK6 (Fig 2.4).
This gene encodes a serine-threonine kinase and cooperates with HIF-1α to promote
anchorage-independent growth in ovarian cancer cells; its expression is correlated with
ovarian cancer aggressiveness (83).
While my data did not identify HIF-1α as a major contributor of hypoxia-mediated
changes in patterns of isoform expression, it does influence splicing of portion of genes
transcriptionally induced by HIF-1α. Interestingly, 6 of the 7 putative HIF-1α binding sites
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that occur nearby the first two exons of NEK6, which is where isoform 2 differs
compared to other transcripts of NEK6. Likewise, splicing of MXI1 is directly influenced
by HIF-binding, which impacts alternative promoter usage in this gene (84). Splicing is
differentially regulated in cancer due to a number of biological alterations, including
mutations in spliceosomal genes or mutations in specific splice sites of genes, but also
due to changes in expression of key signaling networks. Hypoxia is a major stress in the
tumor microenvironment that leads to widespread changes in gene expression; here we
observed significant repression of genes involved in pathways known to regulate the
RNA processing and splicing (Figs 2.3, 2.5, 2.6). Because many regulators of splicing
catalysis were repressed in hypoxic cells, I hypothesize that regulated changes in mRNA
splicing may represent an additional layer of gene expression control under hypoxia. In
order to deeply characterize hypoxia-regulated differences in alternative splicing and to
investigate the resulting biological implications, I next carried out an exon-level analysis
of changes in mRNA structure using the mixture of isoforms (MISO) platform (85). Since
the in vitro datasets had nearly twice as many uniquely aligned reads than the in vivo
dataset and the additional advantage of paired-end sequencing, I exclusively used the in
vitro RNA-seq data for this analysis. This provided me with an ideal dataset for
specifically and confidently measuring expression at splice junctions to detect rare and
lowly expressed alternatively spliced forms under hypoxia. These data will be the basis
of Chapter 3, and importantly led to the discovery of a unique alternatively spliced
isoform of the eukaryotic translation initiation factor, EIF2B5, which we show is
selectively induced under hypoxia and acts in opposition to the full-length isoform to
inhibit protein synthesis. Altogether, these transcriptome studies provide strong support
for the inclusion and deep investigation of alternatively spliced transcripts when
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evaluating cellular responses to stress, such as those that occur within the tumor
microenvironment.
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CHAPTER 3
Transcriptome analysis of hypoxic cancer cells uncovers intron
retention in EIF2B5 as a mechanism to inhibit translation

The work in this chapter contributes to a manuscript of the same title
currently under revision in PLOS Biology.
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Introduction

Reduced availability of oxygen, or hypoxia, is a major feature of solid tumors that
contributes to metastasis and resistance to therapy (86). Tumor hypoxia occurs due to
several physiological factors, such as limited diffusion of oxygen and irregular vascular
structure (87). While oxygen levels can be measured directly in tumors, there is an
immediate need to develop non-invasive clinical markers of hypoxic burden in tumors.
Molecular imaging markers such as pimonidazole and fluorescence-based compounds
(88-90) have been developed and refined to specifically label hypoxic tumors, which
allow for specific interrogation of hypoxic gene expression programs within the tumor
microenvironment (25). Hypoxia-mediated changes in expression can be dynamic and
robust, impacting pathways critical to tumor development and survival, such as
angiogenesis, metabolism and macromolecular synthesis (9, 91). Consequently, there is
a nearly universal negative correlation between the level of hypoxia in tumors and
overall survival in patients of many solid cancers, including head and neck squamous
cell carcinoma (HNSC) (19). As such, hypoxia “metagene” expression signatures have
been successfully implemented as a surrogate method to classify tumor hypoxia for
HNSC and other solid malignancies, including breast and prostate cancer (20, 21).
Hypoxic stress influences processing and translation of mRNAs by regulating the levels
and activity of diverse factors including Hypoxia-Inducible transcription Factors (HIFs),
small non-coding RNAs and miRNAs and RNA binding proteins (RBPs) (33-35). For
example, RBPs such as HuR and PTB, bind to and regulate the stability and localization
of key regulators of hypoxic response such as HIF1α (36, 37) and miRNA-199a (38).
Several kinases known to phosphorylate major RBPs and splicing factors are also
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hypoxia-responsive (54), and alternative splicing of select target genes of HIF1α has
been reported in hypoxic cells (50). Likewise, expression of non-coding mRNA isoforms
are induced under hypoxia in part due to changes in splicing (51). Several splicing
factors, including SF3B1, are upregulated in a HIF1α-dependent manner under
physiological conditions of hypoxia in cardiac myocytes (55); however, it remains unclear
precisely how mRNA splicing is regulated during periods of oxygen deprivation in cancer
cells and what the resulting biological implications are. Intriguingly, regulation of splicing
is frequently altered in cancer and is affected by the same signaling pathways that are
differentially regulated in hypoxic tumor microenvironments (53). Many solid cancers
affected by hypoxia display widespread alterations in splicing (66).
While splicing of specific genes has been shown to be dependent on the activity of
HIF1α, I hypothesized that hypoxia-mediated changes on the RNA processing and
transcription machinery could lead to extensive differences in mRNA splicing. Hypoxia
was identified to induce phosphorylation of the C-terminal domain of RNA polymerase II
(RNAPII), which led to enhanced binding of co-factors and increased control of
transcriptional activation of HIF target genes (92).
Additional findings support that changes in the activity and rate of transcription
elongation play a key role in the maturation and processing of mRNAs under hypoxia.
Under hypoxia, there are fewer changes in RNAPII binding near gene promoters, but
instead an increased accumulation of RNAPII observed along gene bodies (93);
differences in transcription elongation are known to impact regulation of cotranscriptional splicing (94-96). Therefore, to better understand the link between
hypoxia-mediated changes to mRNA regulation and to investigate the biological role of
alternative splicing in response to hypoxia in cancer, I deeply sequenced the mRNA of
hypoxic and normoxic HNSC SQ20B cells.
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The data led to the identification of more than 1,000 transcripts affected by alternative
splicing under hypoxia and revealed three types of mRNA splicing as specifically
enriched, including an increase in retained introns in hypoxia compared to normoxia.
Strikingly, for more than 90% of genes in this category, hypoxia increased the
occurrence of retained introns relative to normoxia, which is a phenomenon also
observed in 16 cancer types, including head and neck, colon, breast and lung cancers
(66). Notably, I discovered a unique retained intron in the master regulator of translation
initiation, EIF2B5. More importantly, this retained intron is expressed in multiple cancers
affected by hypoxic fractions and is overexpressed in HNSC tumors relative to normal
tissues. Here I present compelling evidence hypoxia leads to retention of an intron in
EIF2B5 which creates a phylogenetically conserved premature termination codon. This
alternate transcript results in a truncated protein isoform of eIF2Bε predicted to lack
enzymatic guanine exchange factor (GEF) activity. Remarkably, I demonstrate that the
resulting truncated isoform of eIF2Bε is induced under hypoxia, and provide data to
show that this isoform acts in opposition to full length eIF2Bε to inhibit protein synthesis.
Cellular adaptation to hypoxia entails adjusting key metabolic processes, such as
translation, to low energy due to reduced availability of oxygen (49). Control of
translation initiation specifically contributes to downregulation of protein synthesis under
hypoxia, which occurs through phosphorylation of eIF2α by hypoxia-mediated induction
of the integrated stress response (97). Here, I am the first to my knowledge to describe
hypoxia-mediated induction of a dominant-negative isoform of eIF2Bε as a secondary
method to inhibit translation in periods of acute or prolonged hypoxia. I further
investigated how splicing of EIF2B5 is controlled, and uncovered contributions of several
factors, including a weak splice site at the intron:exon junction, hypoxia-induced
expression and binding of SRSF3, and an accumulation of RNAPII specifically at the
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retained intron.

Results

Hypoxia-mediated changes in transcript-level expression
The transcriptomes of normoxic and hypoxic SQ20B cells (maintained in 0.5% O2 for
16h) were compared to identify expression differences at an individual mRNA transcript
level. The RefSeq hg19 reference comprised of 46,017 transcript models was used for
annotation. Of the 24,812 transcripts expressed in SQ20B cells, I detected 3,114 that
significantly changed expression in hypoxia compared to normoxia (P< 0.05, FDR< 5%,
FPKM≥ 0.5). In total, 1,519 transcripts representing 1,473 genes were induced and
1,595 transcripts expressed from 1,563 genes were repressed (FDR< 5%). Pathwaybased analysis identified “cell adhesion”, “response to hypoxia” and “metabolism” among
the most enriched categories for hypoxia-induced transcripts (P<0.01, DAVID GO(81)).
Induction of select HIF1α target genes was validated by qPCR (Fig 2.2). Repressed
genes were involved in regulating processing, stability and translation of RNAs, with
“ribosome biogenesis”, “nucleosome organization” and “RNA splicing” as highly
significant ontology groups (P<0.01). This included core regulators of splicing, such as
the major splicing factor SF1, serine-arginine splicing factors (SRSF1, SRSF3 and
SRSF7), SF3 genes, and many translation initiation factors, including EIF2B family
members, EIF5 and EIF6. Notably, a closer examination of genes involved in regulation
of mRNA transcription, translation and processing, revealed that the clear majority of
these genes were repressed under hypoxia (Fig 3.1A).
Variation in expression of individual transcripts of the same gene by hypoxia could be
masked when analyzing expression changes at the total gene level; therefore, I next
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used levels of individual isoforms to classify genes as hypoxia-responsive (defined as a
gene with one or more individual transcript detected as significantly induced or
repressed, P<0.05, FDR< 5%). This analysis uncovered 50 additional genes which may
not yet be reported as hypoxia-regulated, including genes known to mediate protein
localization, (SEC24B, ARL17A, PLEKHA8, MLPH, STXBP5, MON2, and EXOC1),
MAPKK signaling pathway, (MAP4K3, DUSP22, and MAP3K13) and key regulators of
RNA metabolism, (ZNF519, JDP2, CTBP2, ZNF248, RBM5, NFAT5, CREB3L2,
SMARCA1 and ZFHX3). Consistent with the finding that transcript-level changes
comprise an additional layer of hypoxia-regulated expression changes, only
approximately 3% of genes which expressed multiple isoforms in SQ20B cells have
been reported to be transcriptionally controlled by HIF binding at hypoxia-responsive
elements (HRE) (98), suggesting an HRE-independent mode of regulation. This is not
surprising, as regulation of transcription and mRNA splicing are observed to be distinct
processes which impact different subsets of genes (80).
Next, I focused on those genes that expressed more than one transcript in SQ20B
cells to assess changes in patterns of isoform expression. Of the 5,418 genes identified
to express >1 transcript, 937 of these genes showed hypoxia-induced changes in
expression of 1,015 transcripts (P< 0.05, FDR<5%). Most these genes contained a
single hypoxia-responsive isoform; only 8% of genes that expressed multiple transcripts
showed more than one isoform as significantly changed under hypoxia.
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Functional classification of changes in alternative splicing
I reasoned that hypoxia-responsive isoforms predicted to carry out different functions
than isoforms expressed in normoxia would be the most biologically impactful changes
which warranted further study. Therefore, I used the program MISO (85) to carry out an
additional exon-level approach to identify changes in gene structure based on eight
annotated categories of alternative splicing. Hypoxia led to a change in expression for
1,103 alternatively spliced loci representing 819 unique genes (Fig 3.1B, ΔPsi >10%,
Bayes Factor >20). Notably, there was a significant comparative enrichment for hypoxiainduced changes in three specific event types: expression of alternate last exons (ALE),
retained introns (RI) and tandem 3’ UTRs (Fig 3.1B). For the genes in these three
splicing categories, gene ontology revealed processes central to hypoxic adaptation as
significantly enriched, including “cellular protein metabolism”, “programmed cell death”
and “gene expression” (DAVID GO, P<0.05, Fig 3.1C). Remarkably, nearly 90% of the
genes in the RI category displayed increased retention of introns in hypoxic compared to
normoxic cells (Fig 3.1D). Among these genes was ANKZF1, a gene implicated in

Figure 3.1 (Next page)- Classification of alternatively spliced mRNAs in hypoxic
SQ20B cells. A: Heatmap of RNA processing and splicing factors differentially
expressed in hypoxia compared to normoxia (Fold-changes shown, FDR<5%). B: To
left, plot depicts number of events detected (blue) compared to events with significantly
different expression in hypoxic compared to normoxic cells (red) (Bayes Factor ≥20, ∆Ѱ
> 10%; SE = skipped exon, RI = retained intron, A5SS = alternative 5’ splice site, A3SS
= alternative 3’ splice site, AFE = alternative first exon, ALE = alternative last exon, MXE
= mutually exclusive exon, TUTR = tandem 3’ untranslated region). Specific enrichment
for changes in three event types are starred: ALE, RI, TUTR (***P< 0.001, 2-sample test
for equality of proportions). To right of graph, exon models of the types of splicing
assessed by MISO analysis. C: Gene ontology figure representing functional
enrichment for hypoxia-induced changes in ALE, RI and TUTR categories. D: Percent
spliced in (Psi) values plotted with hypoxia samples (red) overlaid against corresponding
normoxic Psi values (blue). E: PCR validation of intron retention events in EIF2B5 and
ANKZF1 genes. Diagrams to right of gel images of PCR products depict exons as solid
blue and introns as striped rectangles.
42

mitochondrial and endoplasmic reticulum-associated protein degradation (99, 100), the
translation initiation factor EIF2B5, TGFB1 and the metionyl-TRNA synthetase, MARS.
The retained introns in these genes were validated by PCR using primers spanning the
intron junction and cDNA prepared from oligo-dT selected mRNA (Fig 3.1E).
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Strikingly, EIF2B5 stood out as the strongest candidate for further functional studies for
several reasons: (a) hypoxia led to a >40% increase in retention of intron 12 in a
background of an overall 2-fold decrease in total expression of EIF2B5 (∆Ѱ = 0.44,
Bayes Factor >20), (b) the retention occurred specifically at a single locus of EIF2B5 and
(c) retention of intron 12 creates
a premature termination codon
(PTC) that remains in frame with
the coding sequence (Fig 3.2).
The genomic locus around the
PTC is highly conserved even
among lower organisms.
Intriguingly, this stop codon is
part of the 5’ splice site
consensus sequence
“GURAGU” where URA can be
either UAA or UGA (both of
which would create a stop
codon). This suggests a strong
evolutionary pressure to

Figure 3.2: Hypoxia promotes intron retention in EIF2B5 and insertion of an
evolutionarily conserved premature termination codon. Upper: Gene model of
EIF2B5, with sashimi plot of normalized RNA-seq reads for representative matched
hypoxia and normoxia samples (plot created using Integrative Genome Viewer).
Lower: UCSC Genome Browser Vertebrate Conservation track reveals a conserved
stop codon (TAA or TGA), which remains in frame upon retention of intron 12.
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preserve an early termination precisely at this location where inclusion of the PTC may
be influenced through regulation of splice site choice.
A deeper analysis of changes in splicing of EIF2B5 was carried out to closely examine
inclusion of intron 12 and to validate the occurrence of this retained intron using another
method; the software package MAJIQ (101) was used to assess local splicing variation
in EIF2B5 for annotated and de novo splice events. A hypoxia-induced increase in
expression of intron 12 was confirmed using this approach (Fig 3.3) but additional sites
of local splicing variation did not show significant (>20%) hypoxia-influenced changes.

Figure 3.3: Additional analysis of EIF2B5 splice junction reads. A: Splice graph
of 3’ end of EIF2B5 displaying splice junction reads for all normoxia and hypoxia
samples, with arrow signifying intron 12 (created using MAJIQ/VOILA). RNAseq
expression data are reported as mean, normalized read counts at each junction for
all 4 normoxia and 4 hypoxia biological replicates.
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Retention of intron 12 in EIF2B5 is observed in tumors and leads to a truncated
protein isoform
Increased expression of EIF2B5_intron12 was further confirmed by qPCR using intronspecific primers in a reaction with cDNA prepared from oligo-dT selected mRNA (Fig
3.4A). To confirm expression of EIF2B5_intron 12 in additional datasets and assess its
levels in patient samples, The Cancer Genome Atlas (TCGA) was analyzed for
expression of intron 12 in solid tumors known to be affected by hypoxic fractions (17,
102, 103). Expression of EIF2B5_intron12 was detected in samples derived from
numerous solid tumors (Fig 3.4B). Even though the TCGA samples were not specifically
sorted or selected according to levels of tumor hypoxia, the RNA-seq data collected from
solid tumor samples will include hypoxic regions of the tumor tissue, while normal tissue
samples will not contain as many hypoxic cells. Therefore, I predicted that levels of
intron 12 would be higher in tumor relative to normal tissue. Indeed, we observed
significantly increased expression of intron 12 in HNSC samples compared to matched,
normal tissues (Fig 3.4C). This trend was even more apparent with patients in late-stage
disease, with some individuals exhibiting nearly 8-fold increased expression of intron 12
compared to controls (Fig 3.4D). These data suggest hypoxia-induced retention of
EIF2B5 intron 12 may result in meaningful biological effects and encouraged us to test if
this retained intron leads to a truncated protein isoform.
Computational analyses approximate up to 20-35% of alternatively spliced transcripts
could contain PTCs and become targets of non-sense mediated decay (NMD) (43, 44),
however in cases where NMD is inhibited, transcripts can be stabilized and
subsequently translated into truncated proteins (45). Moreover, NMD surveillance
typically recognizes stop codons as premature if the stop occurs more than 50
nucleotides upstream of a splice junction (42).
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Figure 3.4: Expression of EIF2B5 intron 12 is observed in tumors. A: Real time
quantitative-PCR performed with isoform-specific primers in SQ20B cells. Data are
presented as average of 3 independently conducted experiments, with error bars
reported as s.e.m. B: Expression of intron 12 (chr3:183860931-183861231) was
detected in level 1 RNA-seq data of various cancers examined from The Cancer Genome
Atlas (CPM = read counts per million mapped reads); HNSC= head neck squamous cell
carcinoma (n = 301), BRCA= breast cancer (n = 988), COAD= colon adenocarcinoma (n
= 385), GBM= glioblastoma multiforme (n = 153), OV = serous ovarian cancer (n = 412).
C: Expression of EIF2B5_intron12 was measured for head and neck cancer tumors
compared to normal (P<0.0001). D: Expression of EIF2B5_intron12 was grouped by
disease stage for the 417 head and neck tumor samples, and compared to available
matched normal tissues (P = 0.7 x 10-4 Kruskal-Wallis non-parametric test).
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Due to the unusual nature of this intron retention event and the role of hypoxia in
suppressing nonsense-mediated decay (NMD) in an eIF2α phosphorylation-dependent
manner (39), I predicted that this isoform would not be subject to NMD, but would rather
be translated into a truncated protein (Fig 3.5A). Consistent with this hypothesis, the
MAJIQ splicing analysis of EIF2B5 revealed a 40-50% decrease in expression of
remaining exons following intron 12 (Fig 3.3). These data support the notion that
transcripts which retain intron 12 and the subsequent PTC would undergo read-through
of intron 12 into intron 13, resulting in a reading frame for a truncated protein variant.
Indeed, I observed induction of a 65kDa protein isoform of eIF2Bε under hypoxia,
consistent with the predicted PTC inserted upon retention of intron 12 (Fig 3.5B). To
further test whether this 65kDa protein was indeed a truncated isoform of eIF2Bε, I used
siRNA to specifically target the entire EIF2B5 gene or intron 12 alone. Using this
approach, I observed a substantial reduction in the levels of the 65kDa isoform under
both conditions (Fig 3.5C). I additionally observed hypoxia-induced expression of 65kDa
eIF2Bε in the colorectal cancer cell line, RKO (Fig 3.5D), demonstrating that this is not a
cell-line specific event. Moreover, UV-stress (Fig 3.5E), but not thapsigargin-induced ER
stress, also led to induction of the truncated eIF2Bε, suggesting that expression of this
isoform is induced by specific cell stresses. Furthermore, whole cell lysates were
isolated from hypoxic SQ20B cells and proteins migrating at 80kDa and 65kDa were
subjected to liquid-chromatography tandem mass-spectrometry. Peptides corresponding
to eIF2Bε were detected in both the 80kDa and 65kDa size analytes.
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Figure 3.5: Retention of intron 12 leads to a 65kDa isoform of eIF2Bε. A: Protein
model of observed isoforms of eIF2Bε. B: Immunoblot shows induction of a 65kDa
isoform of eIF2Bε in SQ20B cells maintained for various periods in 0.5% or 0.2%
O2. C: Knock-down of eIF2Bε with siRNA targeting the whole gene or intron 12
reduces expression of the 65kDa isoform in normoxic and hypoxic (0.2% 02) SQ20B
cells. NT = non-targeting control siRNA. D: Hypoxia (16h, 0.5% O2) in a colon cancer
cell line, RKO, leads to induction of 65kDa eIF2Bε. E: Immunoblot of SQ20B cells
collected 4h after exposure to UV. F: Protein sequence of eIF2Bε with peptides
identified from LC-MS/MS sequencing highlighted in yellow (shown to right).
Analysis was carried out from gel-purified bands (shown left) corresponding to
approximately 80kDa (top) and 65kDa (lower), which contained peptides of fulllength eIF2Bε and a truncated isoform of eIF2Bε, respectively.
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The peptides corresponding to the 65kDa-sized isoform of eIF2Bε were located near the
N-terminus or middle of the eIF2Bε sequence, consistent with a C-terminal truncation
(Fig 3.5F).
Finally, I carried out an experiment to test for the involvement of NMD in leading to
expression of truncated eIF2Bε. Although NMD is known to be inhibited in conditions of
oxygen deprivation, NMD and alternative splicing are coupled processes, which can lead
to alternative PTC-containing transcripts which ultimately become targets of NMD (104).
To rule out any major contribution of NMD in leading to expression of 65kDa eIF2Bε, we
used siRNA to knock-down expression of UPF1. This experiment failed to produce an
increase in expression of the truncated protein (Fig 3.6), further supporting the notion
that this isoform occurs due to alternative splicing.

Figure 3.6: Knockdown of UPF1 to inhibit NMD does not induce expression
of 65kDa eIF2Bε. Analysis of siRNA knock-down efficiency of UPF1 shown to
the left. Resulting impact of eIF2Bε protein expression in normoxic SQ20B cells
shown to the right.
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Search for -cis and -trans regulators of alternative splicing of EIF2B5
To identify potential regulators mediating retention of intron 12 in EIF2B5, I utilized the
AVISPA tool (105) to carry out a motif analysis of the locus encompassing EIF2B5 exons
12-14. The data revealed a weak splice site at the intron12:exon13 junction, as well as a
possible “GTGAG” splice site downstream of exon 13 (Fig 3.7A). Notably, these motifs
were not identified in a search of additional loci within EIF2B5. As a control, four
additional exon triplets within EIF2B5 (exons 6-8, 7-9, 8-10, and 9-11) were used to
predict the occurrence of alternative splicing using AVISPA. These loci were not
predicted to be alternatively spliced. Altogether, these results suggest that alternative
splicing is significantly more likely to occur at intron 12 locus compared to the upstream
exon triplets tested. An additional non-motif search of regulatory sequence features in
this locus identified the intron immediately downstream of intron 12 as relatively
unstructured (Fig 3.7B). Furthermore, there is a short distance between exon 13 and the
first AG upstream. Both features are known to contribute to weaker splicing potential
(106, 107).
The motif analysis also identified potential trans regulators with binding sites within
this locus which are experimentally predicted to regulate splicing of this region (Fig
3.7A). Interestingly, several of the splicing factors predicted to have the greatest impact
on regulation of this locus also changed expression under hypoxia, including SRSF2,
SRSF3, HNRNPC, HNRNPF, and RBMX (hnRNP-G) which were repressed at the
mRNA level and CELF5 which was induced (Fig 3.1A, FC ≥ |1.2|, FDR < 5%). Upon
closer examination of these splicing factors, we focused in on SRSF3 and CELF5 as
prime candidates to test as regulators of EIF2B5 splicing, due to a large number of
binding sites near the intron12:exon13 junction and that these factors showed >2-fold
changes in mRNA expression under hypoxia.
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Figure 3.7: Analysis of RNA binding factor motifs and regulatory sequence
features at the EIF2B5 intron12 locus. A: Splicing factor motifs determined to have
the largest effects on regulation of the EIF2B5 exons 12 – 14 shown, with color-coded
gene map above and predicted motifs shown below. Black arrows highlight a predicted
weak splice site before exon 13 and an alternate “GTGAG” splice site after exon 13.
Red arrows signify hypoxia-responsive splicing factors. B: Non-motif analysis of other
sequences influencing splicing of EIF2B5. Data generated using AVISPA (47).

I next assayed for changes in protein expression of these splicing factors in hypoxic
cells and observed a reproducible hypoxia-induced increase in SRSF3 protein (Fig 3.8A)
and a slight decrease expression of CELF5. To test for their requirement in the splicing
of EIF2B5 and production of the resulting 65kDa protein isoform, I used siRNA to
knockdown expression of these factors and assayed for changes in expression of 65kDa
eIF2Bε. Upon knockdown of SRSF3, I saw a concurrent disappearance in the
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expression of the 65kDa isoform of eIF2Bε in conditions of normoxia or hypoxia (Fig
3.8B,C), while siRNAs against other RBPs, such as CELF5, did not display the same
effect.
RNA immunoprecipitation assays were next carried out to confirm a direct interaction
between SRSF3 protein and EIF2B5 RNA. The data showed enrichment of SRSF3 at
three exons in the locus containing EIF2B5_intron12 (Fig 3.8D), validating the predicted
binding sites observed in other systems. Furthermore, binding of SRSF3 was increased
in hypoxic cells relative to normoxic cells, providing additional support for the role of
SRSF3 in regulating hypoxia-induced retention of intron 12.

Figure 3.8 (Next page): Functional investigation of SRSF3 contribution to EIF2B5
intron 12 retention. A: Immunoblot of SQ20B lysates to test expression of SRSF3 (Nx =
normoxia, Hx = 16h 0.5% O2). B: Immunoblot analysis of knock-down efficiency of SRSF3
for SQ20B cells (same experiment as panel C). C: Immunoblot of lysates collected from
SQ20B cells treated with 50nM siRNA under 16h 0.5% O2. D: Immunoblot from
immunoprecipitation of SQ20B lysates with SRSF3 antibody in normoxia and hypoxia.
Rabbit IgG was used as a control. RT-qPCR analysis of RNA isolated from the
immunoprecipitation with SRSF3 using primers for (-) control (a region of GAPDH
predicted to contain no binding of SRSF3), and primers for three exons in the region of
EIF2B5_intron12 predicted to have SRSF3 binding.
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Hypoxia-mediated changes in regulation of RNA polymerase II may influence
retention of EIF2B5 intron 12
In addition to the influence of sequence elements, mRNA splicing is a cotranscriptionally regulated process which is impacted by coordination of RNAPII.
Phosphorylation of the C-terminal domain (CTD) of RNAPII is known to impact the rate
of transcriptional elongation, pausing, and the relative rate of splicing (108, 109).
Therefore, I assayed for changes in phosphorylation of the C-terminal domain (CTD) of
the largest subunit of RNAPII in HNSC cells. Surprisingly, we saw a large (>10-fold) and
reproducible increase in levels of phosphorylation at serine 2 residues and a
concomitant decrease in phosphorylation of serine 5 and 7 residues of the CTD in
hypoxic cells compared to normoxic controls (Fig 3.9A). Interestingly, accumulation of
the phospho-Ser2 form of RNAPII has been associated with retained introns compared
to constitutively spliced introns (110). To assay for changes in binding of total and
phospho-Ser2 RNAPII, we used chromatin-immunoprecipitation followed by qPCR. We
observed a significant hypoxia-induced enrichment in both forms of RNAPII at intron 12,
but did not detect the same enhanced binding at another nearby intron of EIF2B5 which
did not undergo intron retention under hypoxia (Fig 3.9B). In strong support of these
data, cells expressing mutant forms of RNA polymerase with slower elongation rates led
to extensive changes in mRNA splicing including specific retention of EIF2B5_intron12
(61). Moreover, 31 of 100 genes we identified to be affected by intron retention in
hypoxia were classified as “rate-sensitive” and displayed altered expression in the RNA
polymerase elongation mutants (61), suggesting that hypoxia-mediated changes in
elongation of RNAPII likely influences splicing of additional loci.
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Figure 3.9: Detection of hypoxia-mediated changes in phosphorylation and
binding of RNAPII. A: Immunoblot of phosphorylated forms of RNAPII in SQ20B
cells. B: Chromatin immunoprecipitation followed by qPCR to determine abundance
of total RNAPII or P-Ser2 RNAPII at EIF2B5 intron 12, an upstream negative control
intron 10, a negative control region of GAPDH ((-) control)) and a RNAPII positive
control region of GAPDH. For panel B - total RNAPII data represent average of n =
3 independently conducted experiments (error bars = S.E.M.) and P-Ser2 data
shown as an average of n = 2 independently conducted experiments.

Those genes alternatively spliced in conditions of slow elongating RNAPII generally
exhibited weaker 3’ splice sites compared to loci insensitive to changes in elongation
rate (61), so we next carried out an analysis of splice site strength for genes affected by
intron retention under hypoxia. This analysis detected significantly weaker 3’ splice sites
for genes with changes in retained introns under hypoxia compared to a control set of
splice sites not affected by hypoxia (Fig 3.10A). Collectively, differential binding of
SRSF3 at the locus of EIF2B5 intron12, a weak splice site coupled with an alternate
splice site, and increased binding of total and P-Ser2 RNAPII provide strong evidence to
support differential splicing of this locus and specific inclusion of intron 12 (Fig 3.10B).
56

Figure 3.10: Analysis of splice site strength in hypoxia-mediated intron
retention and model of EIF2B5 intron retention under hypoxia. A: Analysis of
3’ splice sites carried out using a First Model Markov method to determine
maximum entropy scores, reported as 3’ splice site strength (1). Hypoxia group =
101 unique 3’ splice sites of introns retained under hypoxia; Random group = 252
hg19 3’ splice sites. B: Under acute or prolonged hypoxia, increased
phosphorylation of Ser2-RNAPII accumulates specifically at EIF2B5 intron 12.
Hypoxia increased binding of SRSF3 at this locus, where a weak splice site and
alternate downstream splice site all contribute to retention of intron 12. Thus,
oxygen deprivation leads to an accumulation of intron-12 containing EIF2B5
transcripts which result in a truncated reading frame due to insertion of a
termination codon.
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The 65kDa isoform of eIF2Bε acts in opposition to full-length eIF2Bε to inhibit
protein synthesis
Next, I tested whether the expression of 65kDa eIF2Bε has an impact on the biological
function of the endogenous, full-length eIF2Bε protein. The truncated protein isoform
created from retention of intron 12 is predicted to lack two critical domains which occur in
the C-terminus (Fig 3.5A): a guanine nucleotide exchange (GEF) domain and a region
required for interaction with eIF2α (111). Thus, I hypothesized that the 65kDa isoform of
eIF2Bε would inhibit translation and lead to reduced protein synthesis. To test this, I
constructed a plasmid expressing the truncated 65kDa isoform using site-directed
mutagenesis to insert a stop codon within 3 nucleotides from where retention of intron 12
results in a PTC (Fig 3.11A). Expression of this mutated version of eIF2Bε under
normoxic conditions resulted in the appearance of a 65kDa protein isoform consistent
with the size of the endogenous protein that is induced under hypoxia (Fig 3.11B).
To analyze the impact of expression of the truncated isoform on protein synthesis, I used
pulse-labeling of 35S methionine/cysteine in cells expressing 65kDa eIF2Bε, full-length
eIF2Bε or empty vector. There was a pronounced and reproducible decrease (approx.
30%), in total protein synthesis in cells expressing 65kDa eIF2Bε (Fig 3.11B,C)
compared to empty vector, while expression of full-length eIF2Bε did not have the same
effect. Translation was assessed relative to cells expressing empty vector as a control
because endogenous full-length eIF2Bε remains stably expressed under hypoxic
conditions and is not induced. Additionally, expression of full-length eIF2B has been
shown to destabilize of ternary complex formation (112). In support of these data, I also
observed a decrease in the total polysome profile of cells expressing 65kDa eIF2Bε
compared to control (Fig 3.11D), and comparable to the decrease in translation
observed in hypoxic conditions (Fig 3.11E).
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Figure 3.11 (Next page): Expression of a 65kDa isoform of eIF2Bε leads to a global
decrease in protein synthesis. A: Site-directed mutagenesis was used to introduce a
stop codon into EIF2B5 (within one codon of where intron retention introduces an early
stop). B: Expression of full-length (WT) or mutated eIF2Bε (mutant) was performed for
24h in SQ20B cells (upper), followed by pulse-labeling with 35S methionine/cysteine
(lower) to measure changes in protein synthesis compared to expression of an empty
vector pCMV6-AC (EV). Cells treated with cyclohexamide (CHX) were used as a control
for inhibition of translation initiation. C: Image quantification of total 35S signal from
autoradiographs of 4 independently conducted experiments. Data collected from n = 4
independently conducted experiments, *P <0.01 (Student’s t-test). D: Polysome profile
depicts SQ20B cells expressing the 65kDa isoform of eIF2Bε for 36h compared to cells
expressing control pCMV6-AC, with supporting immunoblot shown above. E: Polysome
profiling of hypoxic vs. normoxic SQ20B cells.

59

60

Expression of 65kDa eIF2Bε promotes cellular adaptation to hypoxia
Because downregulation of translation is one mechanism by which tumors cells
overcome hypoxic stress (8), I predicted that expression of 65kDa eIF2Bε and the
resulting repression of translation may promote survival of hypoxic cells. To test this,
clonogenic assays were performed to measure survival and proliferation. The surviving
fraction of cells expressing 65kDa eIF2Bε decreased under normoxic conditions, but was
significantly higher when cells were grown in 0.5% O2 conditions for either 16h (Fig
3.12A) or 24h (Fig 3.12B).

Figure 3.12: Expression of 65kDa eIF2Bε confers a survival advantage
under hypoxia. A: Clonogenic assay of SQ20B cells expressing control plasmid
(pCMV6.AC) or 65kDa eIF2Bε in normal oxygen or 0.5% O2 for 16h. Analysis of
three biological replicates quantified to right (P-value reported for student’s t-test).
B: Same experiment repeated at 0.5% O2 for 24h. Analysis of three biological
replicates quantified to right (P-value reported for student’s t-test).
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Discussion

I believe that these findings represent the first case of splicing as a previously
uncharacterized mode of translational control under conditions of hypoxia. I demonstrate
that decreased oxygen in cancer cells leads to extensive changes in mRNA splicing,
resulting in a striking increase in retention of over 100 introns. A unique hypoxia-induced
intron retention in the master regulator of translation initiation, EIF2B5, leads to a
previously undescribed 65kDa isoform of eIF2Bε, that decreases overall protein
synthesis in HNSC cells. Full-length eIF2Bε is a necessary component of the eIF2B
complex, containing both the active GEF domain and a region for association with eIF2α
(47); this complex binds eIF2α and exchanges GDP for GTP to initiate translation.
During hypoxia, eIF2α is phosphorylated and translation initiation is inhibited, and was
demonstrated to be critical for cell survival under extreme hypoxia. However, hypoxiainduced phosphorylation of eIF2α is reversible and not long-lasting (8). Thus, I propose
that during periods of acute or prolonged hypoxia, intron retention in EIF2B5 leads to
expression of a truncated dominant-negative isoform to further inhibit protein synthesis
in cancer cells (Fig 3.13). Expression levels of 65kDa eIF2Bε are consistently
upregulated in hypoxia, with the greatest induction of this isoform observed at stringent
(0.2% O2) and prolonged (≥16 h) hypoxic conditions. Altogether, these data establish a
biological role for the 65kDa isoform of eIF2Bε in promoting adaptation to hypoxic stress
in cancer cells. The question remains as to whether induction of this isoform is a cause
or effect of tumorigenesis. The results from the clonogenic assay suggest a role for
65kDa eIF2Bε in tumor growth, however additional animal studies to evaluate its
potential to influence tumor formation are needed and will be a focus of future work.
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Figure 3.13: Model of the role of the hypoxia-induced 65kDa isoform of
eIF2Bε in inhibiting translation initiation during periods of prolonged or
acute hypoxia. Retention of intron 12 under hypoxia leads results in a 65kDa
isoform of eIF2Bε. This isoform lacks the functional guanine exchange factor
(GEF) domain and acts opposite to the full-length isoform to inhibit translation
during periods of prolonged hypoxia.

Regulation of intron 12 retention in EIF2B5, like splicing of most loci, appears to be
influenced by several factors, including a weak splice site, secondary structure of
EIF2B5 transcripts, and binding and coordination of RNA processing factors and
spliceosome machinery. Unique sequence features may also explain why some introns
are retained under stress while others are not. Retained introns are short and high in GC
content (113, 114). Intron 12 is relatively shorter and higher in GC content, compared to
other introns in EIF2B5, suggesting that sequence elements in this region may
specifically promote retention of intron 12 compared to other introns. In addition, the
AVISPA analysis of sequence features detected a relatively weaker splice site at exon
13 and a possible “GT” alternate splice site in intron 13, which likely influence splice site
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choice at the junctions surrounding intron 12 under hypoxic stress. Additionally, I
observed downregulation of many genes that regulate splicing and RNA processing,
including some of which were predicted to bind at the EIF2B5_int12 locus. There is
evidence that global downregulation of splicing factors and RNA binding proteins can
promote intron retention in a regulated manner during other physiological responses or
processes, such as hematopoiesis (3). However, I uncovered that the splicing factor
predicted to contain the most binding sites within the EIF2B5_intron12 locus, SRSF3,
was induced at the protein level under hypoxia and exhibited increased binding at
EIF2B5 exons 12 and 13 under hypoxia (Fig 3.8). Reducing levels of SRSF3 decreased
expression of the 65kDa protein isoform, suggesting a major role of SRSF3 in regulating
splicing and intron retention in EIF2B5 in hypoxic cells.
Regulation of EIF2B5 intron 12 as well as additional introns retained under hypoxia
are likely influenced by hypoxia-mediated changes in activity of RNAPII. Under hypoxia,
changes in phosphorylation of the C-terminal domain of RNAPII influence expression of
HIF-1α target genes by affecting the binding of co-factors and the kinetics of
transcriptional activation (92). Hypoxia-mediated changes in the rate of transcriptional
elongation may explain why we observed an enrichment of splicing changes at the 3’
end of genes (i.e. ALE, TUTR and RI categories). Several RNA binding proteins,
including polyadenylation factors and splicing regulators interact specifically with
phospho-Ser2 modifications of the CTD (115). Intriguingly increased occupancy of
phospho- Ser2 RNAPII is associated with retained introns compared with constitutively
spliced introns (110). Our data support that this mechanism may act to promote retention
of intron 12 in EIF2B5, and future work by our group will determine whether this
translates to other hypoxia-induced retained introns as well. This regulation could
depend on differences in -cis sequences around the splices site, which have been
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reported to occur in genes sensitive to changes in RNAPII elongation events(61);
likewise, our data showed an enrichment for relatively weak 3’ splice sites at genes
affected by intron retention under hypoxia compared to control genes (Fig 3.10A).
The physiological relevance of these findings is underscored by the fact that EIF2B5
intron 12 is expressed in multiple types of cancer known to contain hypoxic fractions and
more importantly, is overexpressed in tumor vs. normal tissues of HNSC patients. Intron
retention has now been observed in most cancers, further highlighting the need to
understand this important form of RNA processing and regulation in a cancer context.
My data suggest that many hypoxia-responsive isoforms have the potential to influence
key biological pathways in cancer cells. For example, the retained intron in TGFB1 leads
to a different 5’ UTR and alternate transcription start site, which would code for a 416
amino acid peptide instead of the full-length 689 amino acids. This change in the Cterminus would affect part of a FAS1 domain, involved in binding integrin to regulate cell
adhesion, as well as an EMI domain which is thought to be a protein-protein interaction
domain. These data highlight the need to include alternative splicing and individual
mRNA transcript levels in gene expression studies to investigate cellular adaptation to
hypoxia, as well as include these changes in splicing in the development of prognostic
hypoxia gene expression signatures.
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CHAPTER 4
Discussion & Future Directions
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Summary

Here I presented evidence that under acute or prolonged hypoxia, alternative splicing
leads to a retained intron in the master regulator of translation initiation, EIF2B5.
Strikingly, retention of this intron creates a phylogenetically conserved pre-termination
codon which results in a truncated form of eIF2Bε lacking the enzymatic GEF activity. A
resulting truncated isoform of eIF2Bε is induced under hypoxia, which acts in opposition
to full length eIF2Bε to inhibit protein translation and confer a survival advantage to
hypoxic cells.
EIF2B5 was among 100 genes with changes in intron retention in conditions of
low oxygen. Surprisingly, over 95% of these genes showed an increase in a retained
intron under hypoxia, providing evidence that regulated control of intron retention is a
way to exert fine control over the repertoire of hypoxia-responsive mRNA isoforms
expressed in cancer cells. In support of this notion, these genes were functionally
enriched to carry out biological roles critical to cellular adaptation to hypoxia, such
regulation of cell cycle, gene expression, RNA splicing and programmed cell death (Fig
3.1, DAVID Gene Ontology, P< 0.05). This class of genes may be commonly regulated
by a combination of relatively weak 3’ splice sites (Fig 3.9, 3.10) and accumulation of a
form of RNA polymerase II (RNAPII) phosphorylated on serine 2 residues of the Cterminal domain. These data open up a novel area of investigation to study the
contribution of hypoxia-mediated phosphorylation of RNAPII in regulation of intron
retention in hypoxic cells.
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Control of intron retention in hypoxic cells: investigating the impact of changes to
RNAPII elongation & co-transcriptional processing
Regulated pausing of RNAPII near promoters is one mechanism to control expression of
stress responsive genes, including genes that respond to oxygen deprivation. The Cterminal domain (CTD) tail of the largest subunit of RNAPII, Rpb1, contains 52 repeats
of the peptide sequence, “YSPTSPS.” Phosphorylation of serines 2, 5 and 7 play roles in
regulating several steps of transcription including initiation, elongation and termination
(116). Under moderate hypoxia, the hypoxia-inducible transcription factor, HIF-1α,
enhances recruitment of two complexes (Mediator/CDK8 and the Super Elongation
Complex) at target gene promoters, which in turn impact phosphorylation of the CTD of
RNAPII to control transcriptional elongation (92). While phosphorylation of RNAPII-Ser2
along with phospho-Ser5 regulate release and productive elongation of RNAPII to initiate
transcription, P-Ser2 is also observed in increasing amounts moving toward the 3’ end of
genes. In the context of splicing, phosphorylation of the CTD has impacts on mRNA
processing beyond transcriptional activation, with as many as 100 proteins observed to
associate with the CTD (117). Several RNA binding proteins with roles in 3’ end
processing of nascent transcripts, including polyadenylation factors such as PCF11 and
splicing regulators CDK12 and CDK13, interact specifically with phospho-Ser2 of the
CTD (115). Additionally, binding of P-Ser2 RNAPII is significantly enriched at retained
introns compared to constitutively spliced introns (110). Although hypoxia-mediated
changes in phosphorylation of the CTD have not yet been linked to regulation of splicing,
I demonstrated increased binding of total and phospho-Ser2 forms of RNAPII at the
retained intron 12 of EIF2B5 under hypoxia (Fig 3.1), providing support that increased
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phopsho-Ser2 may contribute to changes in splicing of hypoxic cells, specifically by
promoting retention of select introns.
The RNA-Seq data revealed differential expression of genes regulating RNAPII
in hypoxic cells (Fig 2.1) and a large and reproducible increase in levels of
phosphorylation at serine 2 residues at several different durations of low oxygen (Fig
3.14). In the context of regulated intron retention, several groups have specifically linked
slowly elongating or paused RNAPII to changes in splicing, including increased intron
retention (2, 61, 115, 118). This regulation is influenced by stressors such as UV
exposure, -cis RNA sequences and co-factors which interact with the CTD of RNAPII.
Unsurprisingly, I observed that each of these factors contributed to increased retention
of intron 12 in EIF2B5 (see Figs 3.2-3.5, 3.9). While these data provided strong
preliminary evidence to implicate changes in transcription rate and regulated intron
retention in conditions of hypoxia, additional experiments aimed to examine the causal
link between hypoxia-induced changes in phosphorylation of RNAPII and increased
intron retention are needed.
To start, cells should be collected for immunoblot analyses at additional
concentrations of oxygen at varying time-points to better understand the dynamics of
phosphorylation at the CTD under hypoxia. Additionally, it is critical to investigate to what
extent phospho-Ser2 contributes to intron retention under hypoxia by identifying how
many genes with retained introns exhibit increased binding of P-Ser2 RNAPII under
hypoxia. This can be addressed experimentally by either utilizing chromatin
immunoprecipitation (ChIP) followed by sequencing to carry out a genome-wide scan of
P-Ser2 RNAPII abundance or by targeting select introns of the 100 genes affected by
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Figure 4.1: Schematic of experimental design to genetically block
phosphorylation of P-Ser2 in the CTD of RNAPII. A: Tetracycline-off expression
system to express the largest subunit of RNA Pol II (Rpb1) which contains the CTD
repeat region in which the second serines (Ser2) have been mutated to
unphosphorylatable alanines. The plasmid Rpb1 also contains a point mutation which
confers resistance to the RNA Pol II inhibitor α-amanitin. (Image modified from
manuscript describing initial plasmid development (2)). B: Upon removing tetracycline,
expression of this S:A mutant is induced and addition of α-amanitin can be used to
repress expression of endogenous Rpb1.

intron retention under hypoxia and assaying for binding of P-Ser2 RNAPII individually by
ChIP-qPCR.
Furthermore, I have obtained a plasmid which expresses a form of the largest
subunit of RNA Pol II, RPB1, in which the second serine of each C-terminal domain
repeat series has been mutated to an alanine (115). Overexpression of this plasmid,
while depleting levels of endogenous wild-type RPB1 with the drug α-amanitin (Fig 4.1),
can be used to block the phospho-Ser2 form of RNAPII. These cells can then be used to
test if intron retention in EIF2B5 is reduced under hypoxia in the absence of phosphoSer2 compared to cells with normal levels of wild-type RPB1. These studies can be
extended to include the other 100 genes observed to undergo intron retention in hypoxic
conditions or loci determined to show increased binding of P-Ser2 RNAPII as identified
by ChIP-seq. One study identified that moderate hypoxia (1% oxygen for 24h) can
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induce phosphorylation of serines 2 and 5 in HCT116 human colorectal carcinoma cells
(92). These data led to a model by which regulated pauses of RNAPII at gene promoters
help to coordinate the gene expression response to hypoxia. It would be fascinating to
explore pausing of RNAPII beyond gene promoters and investigate how changes to the
elongation rate of RNAPII are affected in hypoxic cells. In the broader context of
regulated intron retention, hypoxic stress may represent an ideal model for a physiologic
stress under which to investigate mechanisms that control intron retention. However, if
RNAPII is a major contributor to this process, understanding exactly how hypoxia alters
rates of transcription would be a critical first step. In the context of UV stress, which also
induced intron retention in EIF2B5 (as evidenced by induction of the 65kDa protein
isoform), blocks to transcription elongation arise due to DNA damage caused by the UV
exposure which leads to pyrimidine dimers which alter RNAPII transcription kinetics and
subsequently impact regulation of splicing (118). Based on my data, hypoxia-mediated
changes to changes in transcription elongation are more likely explained by changes in
cell signaling and phosphorylation of the CTD. To study changes of transcription
elongation more directly, global run-on (GRO) sequencing experiments could be
performed in hypoxic and normoxic cells to examine how oxygen deprivation influences
nascent RNAs, elongation rates and RNAPII pausing.
To characterize the -cis sequence elements with the greatest influence on intron
retention, a more comprehensive analysis of RNA sequences surrounding the retained
introns for all genes affected by changes in intron retention under hypoxia should be
conducted. These data would allow for the characterization of common sequence
features that influence intron retention under stress. Analyses to consider should include
a complete evaluation of splice site strength at the 5’ and 3’ splice sites of these genes
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compared to splice sites of genes unaffected by alternative splicing, a computational
search for cryptic alternative splice sites at loci containing introns retained under
hypoxia, an assessment of RNA secondary structure at these loci and an analysis of the
lengths and GC content of hypoxia-retained introns compared to constitutively spliced
introns.
Testing the functional requirement of a weak splice site and usage of an alternate
downstream splice site in leading to the expression of 65kDa eIF2Bε under hypoxia
could be carried out by blocking retention of intron 12 in EIF2B5 by targeted disruption of
the 3’ splice sites. Then, the ability of these cells to suppress translation under hypoxia
can be evaluated. These experiments would significantly add to the impact of this study,
since all the work to determine the role of 65kDa eIF2Bε thus far has been carried out in
the context of inducing 65kDa eIF2Bε expression, but not yet in the absence of this
isoform. To solidify its requirement in the decreased protein synthesis observed in
hypoxic cells, the complementary experiment would be to block the retention of intron 12
in hypoxic cells and test if translation is suppressed to a lesser degree than cells able to
induce 65kDa eIF2Bε. However, to achieve this is technically difficult. Permanent
genome-editing techniques, such as CRISPR, which could be aimed at removing intron
12 from the genomic locus encoding EIF2B5, would also impact the maturation of
mRNAs expressing 80kDa full-length isoform of eIF2Bε. Even a more targeted approach
to disrupt the premature-stop codon introduced by intron 12 would likely alter normal
splicing of full-length EIF2B5 transcripts since the stop codon occurs in a highlyconserved area of the 3’ splice site. A way to transiently block the inclusion of intron 12
and disrupt its splicing could be to introduce anti-sense morpholinos, which will bind to
complementary sequences and sterically hinder binding of splicing factors at a particular
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site. Morpholinos are commonly used to disrupt alternative splicing of skipped exons,
however little has been done to test their use in blocking or promoting retention of
introns. Our data identified a potential mechanism for intron 12 retention by which under
hypoxic stress, a weak 3’ splice site at the intron12:exon13 is not used, but an alternate
downstream 3’ splice site may be used instead (Fig 3.7). Targeting the 3’ splice site
used in the normal splicing of full-length EIF2B5 transcripts could be tested first.
Morpholinos could be designed to block this 3’ splice site in cells under normoxic
conditions, to see if disrupting this site would promote usage of the alternate
downstream 3’ splice site and cause induction of the 65kDa protein isoform. Then, in a
separate experiment, morpholinos designed to block binding at the alternate
downstream 3’ splice site could be used in hypoxic cells to validate selection of the
alternate 3’ splice site is necessary for expression of intron 12-containing transcripts and
induction of the 65kDa protein isoform. These cells could then be used to verify that
expression 65kDa eIF2Bε is required to repress translation to the fullest extent under
conditions of prolonged or acute hypoxia. These studies could provide one of the first
examples of targeting weak 3’ splice sites to study mechanisms of intron retention under
cellular stress.

Conservation of eIF2Bε: determining the action of the 65kDa isoform of eIF2Bε in
regulating translation initiation
The EIF2B5 gene is highly conserved, especially in the region containing intron 12 (Fig
3.2). Beyond the scope of hypoxic cancer cells, the action of 65kDa eIF2Bε is likely
relevant to other physiologic conditions of low oxygen, such as during normal tissue
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development or in non-cancerous diseases like cardiomyopathy. The eukaryotic initiation
factor eIF2Bε, is a necessary component of the five member eIF2B complex. The eIF2Bε
subunit contains both a region which interacts with eIF2α and a catalytic guanine
nucleotide exchange factor (GEF) domain (111). Under normal conditions, eIF2B binds
eIF2α and exchanges GDP for GTP to initiate translation. During hypoxia, eIF2α is
phosphorylated and this process is inhibited. The data presented in Chapter 3
demonstrate that hypoxia induces intron retention in EIF2B5 transcripts, resulting in a
dominant-negative 65kDa isoform of eIF2Bε which may act in parallel to phospho-eIF2α
to further reduce translation in periods of acute or prolonged hypoxia. The hypoxiainduced isoform of eIF2Bε is predicted to lack a portion of the C-terminus containing the
catalytic (GEF) domain and a region known to interact with eIF2α (Fig 3.5). Additional
work to identify the general mechanistic action of this isoform on translation initiation in
both normal and cancer cells could support the notion that this isoform may carry out an
evolutionarily conserved role in conditions of physiologic hypoxia in normal tissues.
To begin, experiments to verify that 65kDa eIF2Bε forms inactive eIF2B
complexes lacking functional GEF activity could be carried out using a plasmid harboring
an N-terminal tagged version of eIF2Bε. Immunoprecipitation could be performed with
cells expressing this plasmid and an antibody against the N-terminal tag. Then an
immunoblot incubated with antibodies against the other eIF2B complex members could
be used to test for their association with 65kDa eIF2Bε. In addition to the other complex
members, antibody against total and phospho-eIF2α could also be utilized on the
immunoblot to determine whether complexes containing 65kDa eIF2Bε lose some ability
to interact with eIF2α. Following the experiments to study the formation of the eIF2B
complex, assaying for the GEF activity of complexes containing either full-length or
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65kDa eIF2Bε would provide direct evidence for the 65kDa isoform acting as a
dominant-negative to oppose the function of full-length eIF2Bε.
Additional studies to further delineate the relationship between inhibition of
translation due to phospho-eIF2α or caused by induction of 65kDa eIF2Bε would also
strengthen the hypothesis of a conserved role for 65kDa eIF2Bε. Adaptation of cells to
hypoxia entails adjusting key metabolic processes to reduced energy availability
emanating from lower oxygen availability (9, 32, 119). Control of translation initiation has
been specifically shown to contribute to downregulation of protein synthesis under
hypoxia, which occurs through phosphorylation of eIF2α by hypoxia-mediated induction
of the integrated stress response (ISR) (97). An interesting observation from my work
showed that upon siRNA knockdown of eIF2Bε, there was delayed induction of
phospho-eIF2α (Fig 3.5). I believe this further supports the notion that induction of
65kDa eIF2Bε acts in parallel with stress-induced phosphorylation of eIF2α to maintain
suppressed translation in hypoxic conditions. Perhaps when levels of 65kDa eIF2Bε
become too high, cells can no longer tolerate immediate and long-lasting
phosphorylation of eIF2α. Moreover, it has been shown that a S51A mutation blocks
hypoxia-mediated inhibition of translation up to 10h under hypoxic conditions (8), but not
completely. This supports the existence of a secondary mechanism to inhibit protein
synthesis in conditions of hypoxia. To investigate the cross-talk between these two
pathways, expression of 65kDa eIF2Bε should be induced in cells expressing nonphosphorylatable eIF2α. This could be achieved by either using cells with the S51A
serine:alanine mutation to block phosphorylation of eIF2α or by adding expression of
GADD34 (the phosphatase able to remove phosphoryl groups from eIF2α (48)) in these
cells. While we observed that thapsigargin-induced ER stress did not lead to an
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induction of 65kDa eIF2Bε, it would be interesting to test if other ISR initiators, such as
nutrient deprivation, upregulate 65kDa eIF2Bε to see if these two pathways converge
during other cellular stress responses.

Investigating the tumorigenic potential of 65kDa eIF2Bε
The clinical relevance of these findings is emphasized by the fact that EIF2B5 intron 12
is expressed in several types of solid cancer known to contain hypoxic fractions and is
overexpressed in tumor versus normal tissues of head and neck cancer patients (Fig
3.4). While mutations in EIF2B5 have been linked to Vanishing White Matter Disease
(120), there have not yet been reports of mutations in EIF2B5 in association with cancer.
However, defects in eIF2B guanine nucleotide exchange activity have been observed in
a model of oncolytic virus infection in mouse embryonic fibroblasts (121). The authors
posit that this alteration in the GEF function is due to upregulation of full-length eIF2Bε in
transformed versus primary mouse embryonic fibroblasts. However, it would be
interesting to look for activation of the 65kDa isoform of eIF2Bε in this model and to test
cellular sensitivity to the oncolytic vesicular stomatitis virus in the presence and absence
of 65kDa eIF2Bε. From what I have gleaned about the function of 65kDa eIF2Bε in
downregulation translation in our system, I predict that blocking induction of this isoform
may promote susceptibility to oncolytic viruses and subsequently prevent tumorigenesis
in these cells.
An essential question about the role of 65kDa eIF2Bε in tumor growth is whether
induction of this isoform is a cause or effect of tumorigenesis. The results from the
clonogenic assay suggest a role for 65kDa eIF2Bε in tumor growth (Fig 3.12). Moreover,
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immunoblot analyses of tumors established with SQ20B cells in mice showed elevated
levels of 65kDa eIF2Bε in tumor relative to normal tissue (Fig 4.2) supporting this idea.
However, additional cancer cell assays and animal studies are necessary to fully
evaluate its potential to influence tumor formation. Experiments to test the influence of
65kDa eIF2Bε on tumor growth and formation should first be carried out in vitro for
several cancer cell lines and include testing for induction of 65kDa eIF2Bε in higher and
lower concentrations of oxygen to mimic the range of oxygen levels observed in
malignant tissues, performing soft agar assays to test for anchorage-independent cell
growth and developing cell lines stably expressing 65kDa eIF2Bε for future animal work.
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Figure 4.2: Expression of 65kDa eIF2Bε is observed in tumors established
with SQ20B cells in nude mice. Left shows lysates prepared from four
different tumor samples harvested from four different mice. Normal tissue
samples are included to the right. All samples were processed on the same
immunoblot for direct comparison. (Tissue abbreviations: Pancreas, Spleen,
Liver, Muscle).
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Lysates prepared from tumor and control tissues from tumor-bearing mice of varying
ages can be used to determine how early during tumor formation the endogenously
expressed 65kDa eIF2Bε isoform is induced. To assay for the tumorigenic potential of
65kDa eIF2Bε, tumors can be established in mice using cells stably expressing 65kDa
eIF2Bε to test if this isoform influences the time for these mice to develop tumors, the
size of tumors and overall survival. Since the clonogenic assays identified a survival
advantage in cells expressing this isoform under hypoxia, it would also be interesting to
test if mice with tumors expressing high levels of 65kDa eIF2Bε contain more hypoxic
areas that are surviving and become more resistant to radiation or chemotherapies
compared to mice with endogenous expression of eIF2Bε.

Implications for refining prognostic gene expression signatures in solid cancers
Altered regulation of splicing represents a naturally occurring mechanism by which
stress-responsive or tumor-specific isoforms that may contribute to tumor growth and
survival can be induced. Intriguingly, intron retention has been observed to occur at
higher levels in tumor tissues relative to normal tissues for most solid cancers in support
of this notion (66). Preliminary analyses suggest that EIF2B5 intron 12 is anti-correlated
with survival in patients with head and neck squamous cell carcinoma (HNSC) (Fig 4.3),
where I observed a modest yet significant negative correlation between the expression
of the locus spanning intron 12 and exon 13 and overall survival (R= -0.101, P = 0.017,
Fig 4.2).
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Low intron 12 = 594
Δ = -59 days
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Figure 4.3: Correlation of expression of EIF2B5 intron 12 with patient survival
in HNC. A,B: Gene maps of EIF2B5 on chromosome 3 displaying the exon probes
used for expression/survival correlation analysis highlighted in light blue (modified
from the UCSC Genome Browser). A= intron 12 locus; B= control locus. C,D:
Expression (RPKM) of the locus encompassing intron 12 through exon 13 (chr3:
183860964-183861353) is correlated with overall survival for 549 HNSC patients,
while expression of exon 4 is not. E, F: Kaplan Meier survival analysis conducted
for the locus containing intron 12 compared to expression of the total EIF2B5.
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However, expression of other exons in EIF2B5 which were unaffected by alternative
splicing did not significantly correlate with survival (Fig 4.2). Kaplan Meier survival
analysis determined that HNSC patients with high expression of the intron 12 locus had
a 59-day reduction in overall median survival time compared to patients with low
expression of intron 12 (Fig 4.2). While this trend did not reach statistical significance,
differences in total gene levels of EIF2B5 alone cannot explain this change in survival
time, as median survival between patients with high versus low expression differed only
by 8 days (Fig 4.2).
Intron retention as well as other modes of alternative splicing are emerging as
key regulatory mechanisms in physiological processes such as hematopoiesis and
pathological conditions such as malignancy. Understanding the regulation and biological
role of hypoxia-mediated alternatively spliced isoforms is leading to a deeper
understanding of cellular adaptation to hypoxia, and this expanse in knowledge is
creating new areas of investigation for targeted therapies. The work in this project has
newly identified splicing as a mechanism of translational control and adaptation to
hypoxia in cancer cells. Both translation and mRNA splicing pathways can be targeted in
cancer, however many hurdles exist to therapeutically ablating such key biological
processes. Disrupting expression of tumor-specific isoforms with key biological roles in
the cellular adaptation to stresses within the tumor microenvironment may present a new
avenue for targeted therapies. As such, it is critical to redevelop current prognostic
hypoxia gene expression signatures to include isoform-level changes in expression.
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CHAPTER 5
Materials & Methods
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UV-LCM of EF-5 labeled tumors
Specifically, 9L gliosarcoma cells were used to establish tumors in a rodent model. At
the experimental endpoint, animals were anesthetized and the bioreductive dye, EF5,
was injected through tail vain at the concentration 30–80 mg/kg 1–2 h before tumor
excision [23]. Tumors were embedded into either low melting agarose or OCT and
stored at −80 °C. In order to maintain the integrity of the RNA, the tissue samples must
be kept free of RNAses and DNAses, which degrade the nucleic acids. Activity of these
enzymes can be partially inhibited by taking several additional measures during the
preparation of tissue slides, including limiting humidity and by preparing samples at a
low temperature. One tumor sample will be sectioned onto several membrane slides at a
thickness of 10 μm tissue slices using a cryostat at −20 °C. Slides are processed in the
same orientation to enable collection of several dissections per slide and eventual
pooling of material collected from slides derived from the same tumor sample. To ensure
optimal conditions, after tissues have been sectioned onto membrane slides and during
the antibody staining protocol, slides are washed thoroughly and then dehydrated with
ethanol. In addition, during incubation periods, slides are stored in 50-ml conical tubes
containing desiccant pellets and kept on ice or in a 4 °C cold room throughout the
experiment. Once slides have been stained with a secondary antibody containing
fluorochrome, laser capture microdissection can be performed. Microdissection is carried
out on areas of the tumor with the strongest EF5 (or other appropriate marker of
hypoxia) signal to collect hypoxic samples. To avoid necrotic tissue, which will also
exhibit a strong EF5 signal due to lack of oxygen, slides must also be stained with a
nuclear stain, such as Hoescht, to enable researchers to distinguish hypoxic cells (with
intact nuclei) from anoxic/necrotic cells (with fragmented nuclei). Areas of the same
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tumor that display little to no signal from the secondary antibody are collected as paired
normoxic controls (see Fig. 4.1a–c for overview; [23]). All material collected by LCM is
immediately frozen on dry-ice pellets and stored at −80 °C until RNA extraction.
Cell lines & culture conditions
SQ20B cells, derived from human head and neck squamous cell cancer, were obtained
from American Type Culture Collection (Rockville, MD). The RKO cells were a generous
gift from Dr. Cho (University of Chicago). Both cell lines were maintained in Dulbecco’s
Modified Eagle Medium (DMEM) media supplemented with 4.5g/L D-Glucose, 1X Lglutamine, 10% Fetal Bovine Serum and 1X Penicillin/Streptomycin and cultured in an
37°C humidified 5% CO2 atmosphere. For oxygen deprivation experiments, cells were
incubated in 37°C humidified 5% CO2 conditions with varying concentrations of O2 in an
INVIVO2 400 chamber (Baker BioScience Solutions).
RNA purification
RNA was isolated from cells using the Trizol reagent (ThermoFisher), and purified
according to the manufacturer’s protocol. All purified RNA was subsequently treated with
DNaseI digestion to remove possible DNA contaminants (Qiagen). The quality of RNA
used for cDNA library preparation was verified using the RNA nano 6000 analysis chip
on a BioAnalyzer 2000 series instrument (Agilent Technologies) to ensure an RNA
integrity value greater than or equal to 9.
cDNA library preparation and high-throughput sequencing
The cDNA libraries for sequencing were prepared from poly(A)+-selected mRNA,
according to Illumina’s TruSeq Stranded mRNA sequencing preparation kit. Briefly, 1µg
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RNA was purified for mRNA. Then mRNA material was fragmented and denatured, in
preparation for first and second strand cDNA synthesis steps. Finally, the 3’ ends were
adenylated to ligate strand-specific adapter sequences to cDNA material and amplified
using PCR. Purity and size of cDNA library products were confirmed using a
BioAnalyzer instrument. Library concentrations were determined via RT-qPCR using the
Library Quantification Kit (KapaBiosystems). The samples were then prepared and
sequenced on an Illumina HiSeq Series instrument.
Analysis of RNA-sequencing data
The sequencing data were aligned using an RefSeq hg19 reference with STAR software
(version 2.3.0.1)(72), resulting in an average of 1.7 x 108 uniquely aligned reads per
sample. The Cufflinks software suite (version 2.1.1) was used for differential expression
analysis, with standard parameters and RefSeq hg19 reference annotations. Gene
ontology analyses were carried out using DAVID software (81).
The mixture of isoforms software, MISO, version 0.5.1 (February 23, 2014 release) was
used for the exon-centric isoform quantification analysis (85). Each of the 4 hypoxia and
normoxia replicates were merged into one, file for each treatment for MISO analysis. For
the exon-centric analysis, the hg19 GFF3 annotation files for each of the splicing event
categories A3SS, A5SS, AFE, ALE, MXE, RI, SE and Tandem UTR, were (downloaded
from http://genes.mit.edu/burgelab/miso/ as human genome (hg19) alternative events
v1.0). Standard analysis parameters were used, with a filter option applied to require a
minimum of 20 reads to support an event identification.
To identify regulatory elements that may affect retention of EIF2B5 intron 12 we used
AVISPA (105). This method, based on computationally derived splicing codes, has been
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used previously to detect and experimentally verify novel regulators of exon splicing in a
variety of experimental conditions (122-124). Since AVISPA was built for analyzing
differential splicing determinants around cassette exons we extracted hg19 coordinates
for Ensembl-defined exons 11-13 and 12-14, then analyzed these two triplet exons
genomic regions via AVISPA. Also tested were exon triplets 6-8, 7-9, 8-10, and 9-11 to
serve as negative controls as these exons are known to be constitutive and not exhibit
intron retention. The splicing related top motifs and regulatory features were defined by
their normalized feature effect (NFE) and their relative enrichment compared to
alternative and constitutive exons. Briefly, the NFE value represents the effect on
splicing prediction outcome if a motif is removed in silico, normalized by the total effects
observed from removing each of the top features in this way.
RT-PCR
PCR reactions were carried out with cDNA prepared from RNA treated with DNAseI
(Qiagen) to minimize contamination of DNA and in a reverse transcription reaction using
oligo-dT primers to enrich for mature mRNA. Reverse transcription was carried out
according to manufacturer’s protocol (Taqman RT reagents). PCR reactions were
carried out in a PTC-100 Thermocycler (MJ Research, Inc.) for 40 cycles, using
annealing temperatures optimal for each primer set. Quantitative PCR reactions were
prepared using Power SYBR Green PCR Master Mix (Applied Biosystems) and carried
out on a QuantStudio 6 Flex Real-Time PCR Instrument (Thermo Fisher Scientific).
RNAi and expression plasmid experiments
SQ20B cells were plated 24-48h before transfection and grown to approximately 60-70%
confluency. RNAi transfections were carried out using a mixure of lipofectamine RNAi
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Max (ThermoFisher) diluted in OptiMEM media with siRNA to 10-50nM, which was
added to cell culture plates in complete DMEM. Cells were placed in incubator for 24h,
at which point the media was replaced. After an additional 24h, cells either harvested or
used for subsequent experiments. For expression experiments, plasmids were
purchased from Origene. Site-directed mutagenesis was used to alter the original
plasmid and introduce a TAG stop codon, and confirmed by Sanger sequencing (see
Figure 6A). Expression plasmids were transfected in cells plated to the same confluency
as described above using a mixture of lipofectamine 2000 reagent (ThermoFisher)
diluted in OptiMEM media with varying concentrations of pCMV expression plasmid
added to cells in complete DMEM. The plates of cells were incubated for 4-12h, at which
point the media was washed off and replaced. Cells were harvested or used for
downstream experiments 24-48h post-transfection.
Immunoblot analyses
Whole cell lysates were collected using a lysis buffer of 2% Triton-X, 1X Complete Mini
protease inhibitor cocktail (Roche) and 1X phosphatase inhibitor cocktail 2 (Sigma) in
PBS. The nuclear/cytosol fractionation reagents (BioVision) supplemented with 1X
phosphatase inhibitor cocktail 2(Sigma) were used to extract cytoplasmic and nuclear
extracts from the same sample. Lysates isolated from frozen tumor and normal mouse
tissue were lysed in a buffer containing: 1% Triton X-100, 50mM HEPES, ph 7.4, 150mM
NaCl, 1.5mM MgCl2, 1mM EGTA, 100mM NaF, 10mM Na pyrophosphate, 1mM
Na3VO4, 10% glycerol, protease inhibitors (Roche #04693116001) and phosphatase
inhibitors (Roche #04906845001). All protein concentrations were determined using DC
protein assay (BioRad). Equal amounts of protein were resolved on 10% or 12% sodium
dodecyl sulfate polyacrylamide gels and transferred to polyvinylidene fluoride
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membranes. Membranes were blocked with 5% non-fat dried milk in TBS-T (20 mM Tris,
137 mM NaCl, 0.1% Tween-20; pH 7.6) and then incubated in a 1:1000 dilution of
primary antibody in 5% milk/TBS-T followed by 1:5000 dilution of secondary antibody in
5% milk/TBS-T. After washing, membranes were treated with ECL chemicals and
exposed to autoradiograph film.
Liquid chromatography tandem mass-spectrometry
The LC-MS/MS was carried out at the Wistar core facility. Complete protocol available
online: https://www.wistar.org/our-science/shared-facilities/proteomics-facility/helpfulinformation.
35

S labeling for measurement of protein synthesis/image quantification

Following transfection experiment, SQ20B cells were incubated with
methionine/cysteine-free media for 30m. For labeling, one set of experimental cell plates
were incubated for 30m with media supplemented with 0.075 mCi/ml [35S]methionine/cysteine, while a second set of plates were incubated with “cold” media
supplemented with non-radioactive 1X methionine/cysteine. Protein was harvested from
the “cold” samples and a protein assay was performed to obtain concentrations. These
proteins were analyzed using standard immunoblot assay conditions. Proteins collected
from the [35S]-methionine/cysteine labeled cells were resolved on SDS-PAGE. The
resulting gel was then fixed using a solution of 20% methanol and 10% acetic acid for
30m, washed with deionized water, and then incubated on a rocker at room-temperature
with enlightening solution (PerkinElmer) for 15-30m. The gel was then dried for 16h
using a Bio-Rad gel drying apparatus and then exposed to autoradiography film at -80°C
for 2h before processing.
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Polysome profiling
Polysome profiling was carried out per previously described conditions (125).
Chromatin immunoprecipitation
For ChIP experiments, SQ20B cells were plated 24h before placing into hypoxia
chamber or standard incubator. Six 10cm plates at 70% confluency were grown in
normoxic or hypoxic (0.5% O2) conditions for 16h, at which time cells were crosslinked
for 10m at room temperature using 1% formaldehyde in minimum essential medium.
Crosslinking was stopped and cells were washed and lysed according to manufacturer’s
protocol (Active Motif ChIP kit #53035). Shearing conditions were carried out for six 20s
pulses at 25% power, with 30s rest in between pulses on ice. Immunoprecipitations were
carried out according to protocol, with 40ug chromatin and 3ug antibody for RNAPII
(Active Motif #39097, mouse IgG #53010) and 60ug chromatin with 3ug (rabbit IgG
Santa Cruz #sc-2027X) or 30ug P-Ser2 RNAPII (Abcam #5095). For the resulting qPCR
reactions, primers specific to EIF2B5 intron 10 and intron 12 were used (Table S1), and
control primers were purchased from Active Motif (GAPDH-2 for RNAPII control #71006,
GAPDH-1 for P-Ser2 RNAPII control #71004, and Negative-1 for a 78bp intergenic
region of chromosome 12 as a negative control #71001).
RNA immunoprecipitation
SQ20B cells were grown in 2 x 150cm tissue culture plates for each condition (normoxia
and a 0.5% hypoxia time-point). Antibody against SRSF3 (SRp20) was purchased from
MBL, Inc. (#RN080PW). Rabbit IgG was provided by the RIP kit for use as a control (RIP
Assay kit, MBL, Inc. # RN1001). Protein A Sepharose CL-4B (GE Healthcare) were
prepared fresh for the beginning of the experiment in a slurry of 75% beads in 25%
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50mM Tris pH 7.5. Beads were pre-washed in PBS before adding 15µg of antibody and
then incubated at 4 degrees with rotation for 4h. At this time, beads were pre-washed
before lysing cells and adding the lysates to the Protein A beads to preclear for 1h at 4
degrees with rotation. Input samples were collected at this time before adding the
precleared lysate to the antibody-bound beads. Samples were incubated for 3h at 4
degrees with rotation. After wash steps, samples were aliquoted for quality control
analysis of the protein. RNA was isolated according to the manufacturer’s protocol and
analyzed using the Nanodrop1000 UV spectrometer. Equal amounts of RNA were then
processed into cDNA and used for subsequent qPCR analysis. Input RNA was used as
a standard to calculate the quantity for each primer. Expression data are reported as the
relative enrichment of SRSF3 immunoprecipitation over the control Rabbit IgG
immunoprecipitation.
Data Availability
All RNA-sequencing files and analyzed gene expression results have been deposited
into the Gene Expression Omnibus as GSE87456. Any other data used in the
preparation of this study can be issued upon request from Dr. Koumenis.
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